WO2008035757A1 - Jelly-like food containing ubiquinol - Google Patents
Jelly-like food containing ubiquinol Download PDFInfo
- Publication number
- WO2008035757A1 WO2008035757A1 PCT/JP2007/068350 JP2007068350W WO2008035757A1 WO 2008035757 A1 WO2008035757 A1 WO 2008035757A1 JP 2007068350 W JP2007068350 W JP 2007068350W WO 2008035757 A1 WO2008035757 A1 WO 2008035757A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ubiquinol
- jelly
- food
- ubiquinone
- oil
- Prior art date
Links
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 title claims abstract description 130
- 229940040064 ubiquinol Drugs 0.000 title claims abstract description 86
- QNTNKSLOFHEFPK-UPTCCGCDSA-N ubiquinol-10 Chemical compound COC1=C(O)C(C)=C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=C1OC QNTNKSLOFHEFPK-UPTCCGCDSA-N 0.000 title claims abstract description 86
- 235000013305 food Nutrition 0.000 title claims abstract description 80
- 239000003349 gelling agent Substances 0.000 claims abstract description 15
- 229920002472 Starch Polymers 0.000 claims description 20
- 229920000159 gelatin Polymers 0.000 claims description 20
- 235000019698 starch Nutrition 0.000 claims description 20
- 108010010803 Gelatin Proteins 0.000 claims description 18
- 239000008273 gelatin Substances 0.000 claims description 18
- 235000019322 gelatine Nutrition 0.000 claims description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims description 18
- 239000008107 starch Substances 0.000 claims description 18
- 235000015110 jellies Nutrition 0.000 claims description 16
- 239000008274 jelly Substances 0.000 claims description 16
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- 229920001817 Agar Polymers 0.000 claims description 8
- 239000008272 agar Substances 0.000 claims description 8
- 235000010419 agar Nutrition 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 8
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 6
- 229920002752 Konjac Polymers 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 6
- 239000000252 konjac Substances 0.000 claims description 6
- 235000010485 konjac Nutrition 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 235000010418 carrageenan Nutrition 0.000 claims description 5
- 239000000679 carrageenan Substances 0.000 claims description 5
- 229920001525 carrageenan Polymers 0.000 claims description 5
- 229940113118 carrageenan Drugs 0.000 claims description 5
- 235000013312 flour Nutrition 0.000 claims description 5
- 229920001277 pectin Polymers 0.000 claims description 5
- 239000001814 pectin Substances 0.000 claims description 5
- 235000010987 pectin Nutrition 0.000 claims description 5
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 5
- 241001312219 Amorphophallus konjac Species 0.000 claims 1
- 230000007423 decrease Effects 0.000 abstract description 8
- 230000009747 swallowing Effects 0.000 abstract description 7
- 235000004213 low-fat Nutrition 0.000 abstract 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 45
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 44
- 235000017471 coenzyme Q10 Nutrition 0.000 description 44
- 229940035936 ubiquinone Drugs 0.000 description 44
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 24
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- -1 sirium Polymers 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 239000000126 substance Substances 0.000 description 10
- 239000013078 crystal Substances 0.000 description 9
- 239000003925 fat Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 244000247812 Amorphophallus rivieri Species 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000013589 supplement Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 229960003495 thiamine Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- XHXUANMFYXWVNG-ADEWGFFLSA-N (-)-Menthyl acetate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(C)=O XHXUANMFYXWVNG-ADEWGFFLSA-N 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- KATNIMBVOAPAGX-UHFFFAOYSA-N Celerin Chemical compound C1=CC(=O)OC2=C(O)C(OC)=CC(C(C)(C)C=C)=C21 KATNIMBVOAPAGX-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000010642 eucalyptus oil Substances 0.000 description 2
- 229940044949 eucalyptus oil Drugs 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- 229940037001 sodium edetate Drugs 0.000 description 2
- 229960004025 sodium salicylate Drugs 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000019157 thiamine Nutrition 0.000 description 2
- 239000011721 thiamine Substances 0.000 description 2
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 150000003544 thiamines Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- 239000001605 (5-methyl-2-propan-2-ylcyclohexyl) acetate Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JHEPBQHNVNUAFL-AATRIKPKSA-N (e)-hex-1-en-1-ol Chemical compound CCCC\C=C\O JHEPBQHNVNUAFL-AATRIKPKSA-N 0.000 description 1
- 150000004057 1,4-benzoquinones Chemical class 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- MVOSYKNQRRHGKX-UHFFFAOYSA-N 11-Undecanolactone Chemical compound O=C1CCCCCCCCCCO1 MVOSYKNQRRHGKX-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CFAKWWQIUFSQFU-UHFFFAOYSA-N 2-hydroxy-3-methylcyclopent-2-en-1-one Chemical compound CC1=C(O)C(=O)CC1 CFAKWWQIUFSQFU-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- PVXPPJIGRGXGCY-DJHAAKORSA-N 6-O-alpha-D-glucopyranosyl-alpha-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@](O)(CO)O1 PVXPPJIGRGXGCY-DJHAAKORSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- TWXUTZNBHUWMKJ-UHFFFAOYSA-N Allyl cyclohexylpropionate Chemical compound C=CCOC(=O)CCC1CCCCC1 TWXUTZNBHUWMKJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108060006004 Ascorbate peroxidase Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- IWXAZSAGYJHXPX-BCEWYCLDSA-N Bisbentiamine Chemical compound C=1C=CC=CC=1C(=O)OCC/C(SS\C(CCOC(=O)C=1C=CC=CC=1)=C(/C)N(CC=1C(=NC(C)=NC=1)N)C=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N IWXAZSAGYJHXPX-BCEWYCLDSA-N 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 235000005747 Carum carvi Nutrition 0.000 description 1
- 240000000467 Carum carvi Species 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229940123239 Cholesterol synthesis inhibitor Drugs 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 235000017788 Cydonia oblonga Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 240000002943 Elettaria cardamomum Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 240000001972 Gardenia jasminoides Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 206010035669 Pneumonia aspiration Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- APTGPWJUOYMUCE-UHFFFAOYSA-N S-Ethyl thioacetate Chemical compound CCSC(C)=O APTGPWJUOYMUCE-UHFFFAOYSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000004976 Solanum vernei Nutrition 0.000 description 1
- 241000352057 Solanum vernei Species 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 208000013200 Stress disease Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HKQKYZRQBYBWSZ-BMJUYKDLSA-N [(z)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-phosphonooxypent-2-en-3-yl]disulfanyl]pent-3-enyl] dihydrogen phosphate Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCOP(O)(O)=O)/SSC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N HKQKYZRQBYBWSZ-BMJUYKDLSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 201000009807 aspiration pneumonia Diseases 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229950009892 bisbentiamine Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000005300 cardamomo Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- JBTHDAVBDKKSRW-UHFFFAOYSA-N chembl1552233 Chemical compound CC1=CC(C)=CC=C1N=NC1=C(O)C=CC2=CC=CC=C12 JBTHDAVBDKKSRW-UHFFFAOYSA-N 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- 239000001752 chlorophylls and chlorophyllins Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 239000001279 citrus aurantifolia swingle expressed oil Substances 0.000 description 1
- 239000001524 citrus aurantium oil Substances 0.000 description 1
- 239000001071 citrus reticulata blanco var. mandarin Substances 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000010636 coriander oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- 239000001941 cymbopogon citratus dc and cymbopogon flexuosus oil Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-L dithionite(2-) Chemical compound [O-]S(=O)S([O-])=O GRWZHXKQBITJKP-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 1
- 229950006836 fursultiamine Drugs 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- OTGHWLKHGCENJV-UHFFFAOYSA-N glycidic acid Chemical compound OC(=O)C1CO1 OTGHWLKHGCENJV-UHFFFAOYSA-N 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000010656 jasmine oil Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 235000021073 macronutrients Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229940102398 methyl anthranilate Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960005419 nitrogen Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000018192 pine bark supplement Nutrition 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- 229940106796 pycnogenol Drugs 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960003656 ricinoleic acid Drugs 0.000 description 1
- FEUQNCSVHBHROZ-UHFFFAOYSA-N ricinoleic acid Natural products CCCCCCC(O[Si](C)(C)C)CC=CCCCCCCCC(=O)OC FEUQNCSVHBHROZ-UHFFFAOYSA-N 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 235000010491 tara gum Nutrition 0.000 description 1
- 239000000213 tara gum Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 229960004747 ubidecarenone Drugs 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/10—Marmalades; Jams; Jellies; Other similar fruit or vegetable compositions; Simulated fruit products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a jelly food containing ubiquinol, which can be easily replenished with ubiquinol essential to a living body by ingesting it in the same way as normal food in daily life, and its use. It is.
- Ubiquinol is a 2-electron reductant of ubiquinone, a benzoquinone derivative widely distributed in the living world.
- Ubiquinol and ubiquinone are localized in mitochondria, lysosomes, Golgi bodies, microsomes, peroxisomes, or cell membranes, and are involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as components of the electron transport system. It is an indispensable substance for maintaining the functions of living bodies.
- Ubiquinone is also called vitamin Q because of its vitamin-like function, and is a component that rejuvenates the body as a nutrient source that restores weak cellular activity to a healthy state.
- ubiquinol and ubiquinone In vivo, ubiquinol and ubiquinone have a certain equilibrium relationship, and ubiquinol / ubiquinone absorbed in the living body is known to be mutually oxidized / reduced. Normally, it is said that 60 to 90% of the total weight of ubiquinol and ubiquinone is present as ubiquinol in the living body! /.
- the ubiquinone content in human heart is reported to be 11.0 g / g between the ages of 19 and 21, compared with 47.2 g / g between ages 77 and 81.
- Non-Patent Document 1 plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals.
- Non-patent Document 4 plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals.
- the ubiquinone content of the LDL cholesterol fraction is reduced (Non-patent document 4).
- ubiquinone has an effect of improving or preventing heart disease, hypertension, obesity, diabetes, cancer, Parkinson's disease, periodontal disease, neurological disease, allergy, fertility, motor ability, immune function, fatigue, etc. Expected.
- Non-patent document 6 ubiquinone administration has been reported to increase cardiac function
- ubiquinone has an effect to improve cardiac diseases such as congestive heart failure, angina pectoris, and myocardial infarction
- Non-patent document 7 Non-patent document 8
- arteriosclerosis hypertension
- diabetes cancer
- periodontal disease allergy, etc.
- Non-patent document 9, Non-patent document 10, Non-patent document 11, Non-patent document 12 Fertility It is known to have an improving effect, an inhibition of LDL cholesterol oxidation, an effect of reducing the number of dialysis in renal dialysis patients, and an effect of enhancing nonspecific immunity (Non-patent Document 13, Non-Patent Document 14).
- Ubiquinone is already used as a treatment for palpitations, shortness of breath, and swelling due to congestive heart failure or mild heart disease.
- ubiquinol In addition to taking ubiquinol in this way, its strength is expected to be useful. In order to increase the absorption, ubiquinol as such is dissolved in oils and fats, and in some cases, surfactants are also added, and it is generally taken as a capsule to prevent oxidation. Is. However, in the case of capsules, they are difficult to take for people with low swallowing ability, such as the elderly and the sick!
- ubiquinol-enriched oil-and-fat-containing foods have been reported as foods containing ubiquinol S, in order to include ubiquinol, a fat-soluble substance, in foods.
- Ubiquinol is dissolved or coexisting in fats and oils.
- Patent Document 1 JP-A-10-109933
- Patent Document 2 JP-A-10-330251
- Patent Document 3 WO03 / 061395
- Non-Patent Document 1 Lipids, 24, 579-584 (1989)
- Non-Patent Document 2 N mark hron, 66, 153-156 (1994)
- Non-Patent Document 3 BioFactors, 1, 303-306 (1988)
- Non-Patent Document 4 Atherosclerosis, 129, 119-126 (1997)
- Non-Patent Document 5 Clinical Investigator, 71, S97-S102 (1993)
- Non-Patent Document 6 Clinical Investigator, 71, S71-S75 (1993)
- Non-Patent Document 7 Inter. J. Cardiology, 68, 23-29 (1999)
- Non-Patent Document 8 Cardiovasc. Drugs Ther., 12, 347-353 (1998)
- Non-Patent Document 9 Atherosclerosis, 148, 275-282 (1999)
- Non-Patent Document 10 Curr. Therap. Res., 51, 668-672 (1992)
- Non-Patent Document 11 Journal of Oral Hygiene, 43, 667-672 (1993)
- Non-Patent Document 12 Clinical and Research, 58, 1349-1352 (1981)
- Non-Patent Document 13 Mol. Aspects Med., 18, S85-S103 (1997)
- Non-Patent Document 14 ⁇ 1 Aspects Med., 15, S213-S219 (1994)
- Non-Patent Document 15 Acta Diabetol., 42, 179-181 (2005)
- the purpose of the present invention is to obtain ubiquinol, which is apt to be reduced or insufficient, in healthy people, even though it is indispensable for the living body by ingesting it in the same way as normal food in daily life. It can be replenished easily and efficiently even for people with lower swallowing ability, such as older people and sick people, and it is a problem in modern people's eating habits! ⁇ ⁇ To provide jelly-like foods and their uses.
- the present inventors use a gelling agent in place of fats and oils to make a jelly form, whereby ubiquinol can be stably and uniformly dispersed and a jelly-like food with excellent absorbability can be obtained. I found out for the first time. Such jelly-like foods are swallowing ability such as elderly and sick It is also useful for people who have fallen. That is, the present invention is as follows.
- One or more gels selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan as a gelling agent [1] or [2] jelly, characterized by using an agent
- Viscosity is 5.0 X 10 2 —1.0 X 10 5 mPa 's and / or hardness is 5 X 10 4 N / m 2 or less [1] to [3] Food.
- the jelly-like food of the present invention can be consumed in the same way as normal food in daily life.
- it is also a problem in the dietary habits of modern people who can easily and efficiently replenish even those with reduced swallowing ability such as elderly people and sick people! / Low calorie favorable for excessive energy Food.
- the jelly-like food of the present invention is characterized by containing ubiquinol.
- the ubiquinol contained may be substantially ubiquinol alone or a mixture of ubiquinone and ubiquinol.
- the ratio is not particularly limited, but it is preferable that the content of ubiquinol is high! /, So that the weight ratio of ubiquinol / ubiquinone. 40/60 or more is preferred 60/40 or more is more preferred 80/20 is more preferred 95/5 is more preferred 99/1 is most preferred.
- the ubiquinol used in the present invention may be produced by any known method such as a synthesis method or a fermentation method. However, if careful consideration is given to safety for living organisms, it can be used for foods such as meat and fish.
- “derived from the fermentation method” means that the preferred stereoisomerism is obtained based on the fermentation method, for example, the (aU-E) -isomer of the (aU-E) -isomer obtained by the fermentation method. It does not prevent the conversion of ubiquinone and / or ubiquinol into a desired ratio of ubiquinol by treatments such as oxidation and reduction while maintaining its solid form. Stereoisomers are analyzed by HPLC by a conventional method.
- ubiquinol used in the present invention is produced by using ubiquinone produced by a conventional method, preferably ubiquinone produced by fermentation, using sodium borohydride, sodium dithionite (hydrosulfite). This can be done by reducing by a conventional method using common reducing agents such as sodium) and zinc. After the reduction, crystallization may be concentrated by chromatography. Ubiquinol can be used whether it is solid, liquid, crystalline or amorphous.
- the ratio of ubiquinone and ubiquinol is usually determined by quantifying the amount of ubiquinone and ubiquinol in a sample by an HPLC system using a UV detector, and calculating the ratio of the amounts. Using a system incorporating a mechanical detector, the ratio of ubiquinone and ubiquinol can be determined from the peak area. In systems incorporating electrochemical detectors, redox substances can be specifically measured and the sensitivity is high! Therefore, when measuring the proportion of ubiquinol present in a sample in a very small amount, Highly useful. Specifically, it can be measured under the following HPLC conditions by incorporating an electrochemical detector manufactured by Shiseido Co., Ltd. into an Shimadzu HPLC analyzer.
- the jelly-like food of the present invention is not particularly limited as long as it is a food having a so-called gel-like form.
- the jelly-like food is a jelly or a jelly-based food by a gelling agent such as gelatin, agar, or konjac. , Tapio power, warabimochi, litter, jam, boiled rice. Further, these gel-like compositions may have solids.
- the material used for the jelly-like food of the present invention is not particularly limited as long as it has an appropriate viscosity added to a gel food raw material or a liquid food raw material.
- the jelly-like food of the present invention is produced by using a gelling agent that is acceptable as a food and, if necessary, heat treatment or addition of water to form a gel or so-called jelly. Touch with force S.
- the gelling agent used in the present invention is not particularly limited, and corn starch, potato starch, potato starch, sweet potato starch, katsu starch, potato starch (warabiko), tapio force starch, and other starches, agar , Gelatin, konjac flour (Darkmananan, galatatomannan), pectin, carrageenan, alginic acid and its salts, sirium, gum arabic, locust bean gum, guar gum, tamarind gum, quince seed gum, cara gum, tragacanth gum, gati gum, Xanthan gum, dielan gum (native dielan gum, deacyl type dielan gum), tara gum, arabinogalatatan, fur celerin, manolemero, curdlan, punoreran, dextran, canolepoxy methylenoresenorelona And cellulose derivatives such as Li ⁇ -time, and the like.
- Starches agar, gelatin, konjac flour, and pectin are preferable. More preferred are agar, gelatin, konjac flour, pectin, kataguri starch, katsu starch, bran starch, tapio force starch. Two or more of these gelling agents do not work.
- the jelly-like food of the present invention is not particularly limited as long as it has a shape and physical properties similar to an elastic semi-solid, so-called jelly or jelly-like beverage. It is preferable to have a viscosity of 5.0 ⁇ 10 2 mPa ′s or more under the temperature condition at the time of ingestion, and the upper limit thereof is preferably 1.0 ⁇ 10 5 mPa ′s or less.
- the hardness is more preferably 5 ⁇ 10 4 N / m 2 or less, which is preferably 6 ⁇ 10 4 N / m 2 or less.
- viscosity means “a material constant indicating the difficulty of liquid flow or the degree of viscosity”, which is referred to as viscosity or viscosity. Viscosity is the property that resists the force of squeezing when friction is applied to the inside when it is applied.
- Hardness here refers to "resistance when compressed at a constant speed”. When a local force (concentrated load) is applied to a substance from outside in a short time, the degree of deformation of the substance indicated at that time is shown. The strength of the resistance against the resultant deformation is determined as hardness. [0030] The viscosity and hardness of food can be measured using a commercially available viscometer (rheometer, creep meter, etc.).
- the jelly-like food according to the present invention can be used as a food for dysphagia and as a dietary supplement.
- the number of elderly people with movement disorders such as bedridden 'severe dementia' and sequelae of stroke is increasing. If the swallowing function is impaired, food and beverages cannot be swallowed normally, and aspiration that is accidentally drawn into the trachea can lead to death of asphyxia and aspiration pneumonia! is there.
- a liquid with a low viscosity like water is most easily swallowed by healthy people, but it is known that a person who has difficulty swallowing is less likely to cause aspiration. Food is used. Naturally, the hardness of the food is also important, and if it is not soft enough, it will be difficult to knead and mix.
- the method for adjusting to the target viscosity and hardness is not particularly limited, and the type and amount of the gelling agent are adjusted, and other thickeners are used as appropriate.
- a known method can be used.
- gelatin and agar or carrageenan are used as a gelling agent, or carrageenan and xanthan gum are used.
- the method includes using native dielan gum in combination.
- An antioxidant, an organic acid, and vitamins may be added to the jelly-like food of the present invention.
- Antioxidants include lycopene, carotenoids, flavonoids, polyphenols, dartathione, selenium, sodium thiosulfate, alpha lipoic acid and its derivatives, pycnogenol, flavangenol, superoxide dismutase (SOD) Glutathione peroxidase, dartathione S transferase, dartathione reductase, force tarase, ascorbate peroxidase, and mixtures thereof.
- SOD superoxide dismutase
- This antioxidants are used as particularly preferred additives from the viewpoint of enhancing the stability of ubiquinol to oxidation and obtaining a more stable and high effect.
- the organic acid is not particularly limited, but examples thereof include succinic acid, succinic acid derivatives, acetic acid, lactic acid, succinic acid, tartaric acid, aspartic acid, oxalic acid, malic acid, malonic acid, fumaric acid, maleic acid, Examples include propionic acid, butyric acid, valeric acid, isochenoic acid, and mixtures thereof.
- Organic acids are preferred in that they can add an appropriate flavor to the jelly-like food of the present invention, which is not only a component useful for the body itself.
- the vitamins are not particularly limited.
- vitamin A vitamin B (vitamin Bl, vitamin B1 derivative, vitamin B2, vitamin B6, vitamin B12, etc.), vitamin C, vitamin D, vitamins, vitamins , Biotin, pantothenic acid, nicotinic acid, and mixtures thereof.
- the vitamin B1 derivative includes thiamine or a salt thereof, thiamine disulfide, fursultiamine or a salt thereof, dicetiamine, bisbuthiamine, bisbentiamine, benfotiamine, thiamine monophosphate disulfide, chicotiamine, otato thiamine, All of the compounds having physiological activity as vitamin B1, such as prosultiamine, can be included.
- antioxidants organic acids, and vitamins may be used in combination of two or more.
- ingredients contained in the jelly-like food of the present invention are not particularly limited as long as they are ingredients that can be used in foods. If necessary, sugars, sweeteners, fruit juices, flavor powders, flavors, antiseptics Agents, colorants, preservatives, etc. can be used.
- the saccharide is not particularly limited, and examples thereof include sucrose, glucose, fructose, lactose, maltose, isomerized sugar, coupling sugar, palatinose, neosugar, reduced starch saccharified starch, xylose, sorbose, lactulose, poly And water-soluble saccharides such as dextrose, and mixtures thereof.
- the sweetener is not particularly limited, and examples thereof include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin, and mixtures thereof.
- the fruit juice is not particularly limited, and examples thereof include apple juice, orange juice, grape juice, melon juice, lemon juice and the like.
- the flavor powder is not particularly limited, and for example, coffee powder, matcha powder, sencha powder, cocoa powder and the like are used.
- the fragrance is not particularly limited, and examples thereof include menthol, carvone, vanetol, cineol, methyl salicylate, cinnamic aldehyde, eugenol, 3 (1-menthoxy) pronone 1, 2-dionole, and chimole.
- Linalool Linalool, linalino acetate, limonene, menton, menthyl acetate, N-substituted paramentan 1-carboxamide, vinylene, octanolenodehydride, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate , Allylcyclohexanepropionate, methylanthranilate, ethinoremethinoreethino glycidate, nonylin, undecalactone, hexananol, ethinoreanoreconole, propinoreanoreconole, butanol Single-flavored products such as soaminoleanolecole, hexenol, dimethylsulfide, cycloten, furfural, trimethylvirazone, ethyllatatate, ethylthi
- the preservative is not particularly limited, and examples thereof include aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citrate, sodium citrate, salicylic acid, Sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid, potassium sorbate, nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate , Butyl paraoxybenzoate Propyl parabenzoate, methyl paraoxybenzoate, 1 menthol, eucalyptus oil, and mixtures thereof.
- the colorant is not particularly limited, and it is possible to use one that is permitted to be added to food, for example, Blue No. 1, Yellow No. 4, Green No. 3, Red No. 5, Lake Examples thereof include dyes, titanium dioxide, red cabbage dyes, red potato dyes, purple potato dyes, gardenia dyes, cochineal dyes, caramel dyes, chlorophylls, and mixtures thereof.
- the preservative is not particularly limited.
- benzoic acid sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citrate, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D sorbitol , Sorbic acid, potassium sorbate, sodium dehydroacetate, isoptyl noroxybenzoate, isopropyl noroxybenzoate, ethyl parabenzoate, butyl parabenzoate, propyl parabenzoate, methyl paraoxybenzoate, propylene glycol , Phosphoric acid, and mixtures thereof.
- the jelly-like food of the present invention may contain a slight amount of fat and oil components.
- the amount of fat used is preferably 10% by weight or less, and preferably 5% by weight or less, based on the total amount of food. More preferably, it is 1% by weight or less, more preferably less than 0.5% by weight.
- ubiquinol can be suitably dispersed in the food, so that the content of fat and oil relative to ubiquinol in the food can be, for example, equal or less, and even less than half. Is not included at all!
- the jelly-like food of the present invention is a general food, as a dietary supplement and a health food, and is low in ubiquinol for not only healthy subjects but also elderly people and sick people with some disease. Can be consumed as a calorie food. Furthermore, it is also useful as a supplement for elderly and sick people with dysphagia. Furthermore, it can also be applied to animals such as pets, which have been difficult to consume in the past.
- a cup or the like In addition to being provided as a jelly loaded in a bag or as a jelly-like beverage filled in a bouch or the like, the user can also prepare a jelly-like powder by cooking such as water and / or heating. Provided as a solid form.
- the amount of the jelly-like food of the present invention is not particularly limited, but the daily dose for adults is lmg to;! OOOmg, preferably 10mg to 500mg, more preferably 30mg to 300mg. .
- a lOOOOg ethanol solution, lOOg liquor, quinone (purity 99.4%) and 60 g L-asconolevic acid were added, and the mixture was stirred at 78 ° C. to carry out a reduction reaction. After 30 hours, the mixture was cooled to 50 ° C, and 330 g of ethanol and 70 g of water were added while maintaining the same temperature. While stirring this ethanol solution (containing ubiquinol lOOg), it was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to obtain a white slurry.
- the obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C), and the wet crystals were further dried under reduced pressure (20-40 ° C). C,;! To 30 mmHg) to obtain 97 g of white dry crystals. All operations except drying under reduced pressure were performed under a nitrogen atmosphere.
- lOOg ubiquinone (purity 99.4%) was dissolved in lOOOg heptane solution at 25 ° C. While stirring, sodium hyposulfite (purity of 75% or more) as a reducing agent was gradually added an aqueous solution prepared by adding 1000 ml of water to lOOg, and a reduction reaction was performed at 25 ° C and pH 4-6. After 2 hours, the aqueous phase was removed from the reaction solution, and the heptane phase was washed 6 times with degassed saturated saline lOOOg. As described above, all operations were performed in a nitrogen atmosphere.
- This heptane phase was subjected to solvent replacement under reduced pressure to prepare a 7% (w / w) ethanol solution of ubiquinol at 50 ° C (containing lOOg of ubiquinol). 50 g of water was added to the ethanol solution, and while stirring, the solution was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to precipitate crystals. All operations are nitrogen Performed under atmosphere. The obtained slurry was filtered under reduced pressure, and the wet crystals were cooled with cold ethanol and cold water.
- a model sample obtained by drying a jelly-like food containing ubiquinol was prepared as follows.
- oily components are separated by solid-liquid separation according to a conventional method, and the oily components adhering to the particles are washed and removed with about 500 g of ethanol, dried at 50 ° C, and ubiquinol is dispersed in gelatin.
- a particulate composition (model sample of jelly-like food) was obtained.
- This composition and the ubiquinol crystals of Production Example 1 were used for rats respectively.
- An evaluation sample was packed in a capsule.
- Cmax maximum plasma concentration of ubiquinone
- AUC area under the time course curve of the concentration of ubiquinone
- ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, citrate Na, vitamins, and a cup-shaped container with sufficient stirring. The jelly-like food containing ubiquinol was obtained. The taste of the resulting jelly-like food was good.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pulmonology (AREA)
Abstract
A jelly-like food containing ubiquinol. It is found out that ubiquinol can be stably and homogeneously dispersed by using a gelling agent as a substitute for a fat or the like. Thus, it becomes possible to easily and efficiently supply ubiquinol, which is essentially required by living bodies but frequently shows a tendency to decrease or shortage, not only to normal people but also to those having disorders in swallowing ability such as aged persons and ill persons. Because of having a low fat content, the above-described jelly-like food is advantageous for modern people with a tendency to take too much energy.
Description
明 細 書 Specification
ュビキノールを含有するゼリー状食品 Jelly-like food containing ubiquinol
技術分野 Technical field
[0001] 本発明は、 日常生活で通常の食品と同様に摂取することにより、生体に必要不可 欠なュビキノールを容易に補給することができる、ュビキノールを含有したゼリー状食 品及びその用途に関するものである。 [0001] The present invention relates to a jelly food containing ubiquinol, which can be easily replenished with ubiquinol essential to a living body by ingesting it in the same way as normal food in daily life, and its use. It is.
背景技術 Background art
[0002] ュビキノールは、広く生物界に分布するべンゾキノン誘導体であるュビキノンの 2電 子還元体である。ュビキノール及びュビキノンは、ミトコンドリア、リソゾーム、ゴルジ体 、ミクロソーム、ペルォキシソーム、或いは細胞膜などに局在し、電子伝達系の構成 成分として ATP産生賦活、生体内での抗酸化作用、膜安定化に関与している事が 知られている生体の機能維持に必要不可欠な物質である。ュビキノンについては、 そのビタミン様の機能からビタミン Qとも呼ばれており、弱った細胞活性を健康な状態 に戻す栄養源として身体を若返らせる成分である。 [0002] Ubiquinol is a 2-electron reductant of ubiquinone, a benzoquinone derivative widely distributed in the living world. Ubiquinol and ubiquinone are localized in mitochondria, lysosomes, Golgi bodies, microsomes, peroxisomes, or cell membranes, and are involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as components of the electron transport system. It is an indispensable substance for maintaining the functions of living bodies. Ubiquinone is also called vitamin Q because of its vitamin-like function, and is a component that rejuvenates the body as a nutrient source that restores weak cellular activity to a healthy state.
[0003] 生体内でュビキノールとュビキノンはある種の平衡関係にあり、生体内に吸収され たュビキノール/ュビキノンは、相互に酸化/還元される事が知られている。通常、 生体内では、ュビキノールとュビキノンの合計重量に対し 60〜90%がュビキノール として存在して!/、ると言われて!/、る。 [0003] In vivo, ubiquinol and ubiquinone have a certain equilibrium relationship, and ubiquinol / ubiquinone absorbed in the living body is known to be mutually oxidized / reduced. Normally, it is said that 60 to 90% of the total weight of ubiquinol and ubiquinone is present as ubiquinol in the living body! /.
[0004] ュビキノンについては食事によって補給される一方、生体内でも生合成されている 事から、正常な状態ではュビキノン及びュビキノールの必要量は充足されて!/、るか に見えるが、これらの生体内での含量は加齢や生体が受ける種々のストレスにより顕 著に減少することが知られている。 [0004] While ubiquinone is replenished by meals, it is also biosynthesized in vivo, so it seems that the necessary amount of ubiquinone and ubiquinol is satisfied under normal conditions! It is known that the content in the body is markedly reduced by aging and various stresses on the body.
[0005] 例えば、ヒト心臓中ュビキノン含量は、 19歳〜 21歳の場合 110. 0 g/gであるの に対し、 77歳〜 81歳では 47. 2 g/gと半減することが報告されている(非特許文 献 1)。また、尿毒症及び慢性の血液透析患者、種々のアレルギー患者の血漿中ュ ビキノン含量は健常人に比較し減少している(非特許文献 2、非特許文献 3)。高脂 血症患者では、 LDLコレステロール画分のュビキノン含量が減少している(非特許文
献 4)。更に、昨今高コレステロール血漿治療剤として汎用されているコレステロール 合成阻害剤の投与が、ュビキノンの生合成をも阻害し、組織でのュビキノン濃度の低 下をもたらしていることが指摘されている(非特許文献 5)。更に、激しい運動や過労 時等、生体内で過酸化物が生成しやすい条件下においても、組織内濃度の減少が 推定されている。 [0005] For example, the ubiquinone content in human heart is reported to be 11.0 g / g between the ages of 19 and 21, compared with 47.2 g / g between ages 77 and 81. (Non-Patent Document 1). In addition, plasma ubiquinone content in uremia and chronic hemodialysis patients and various allergic patients is reduced compared to healthy individuals (Non-patent Documents 2 and 3). In patients with hyperlipidemia, the ubiquinone content of the LDL cholesterol fraction is reduced (Non-patent document 4). Furthermore, it has been pointed out that administration of a cholesterol synthesis inhibitor, which is currently widely used as a therapeutic agent for high cholesterol plasma, also inhibits the biosynthesis of ubiquinone, resulting in a decrease in the concentration of ubiquinone in tissues (non-) Patent Document 5). Furthermore, it is estimated that the concentration in the tissue decreases even under conditions where peroxides are easily generated in vivo, such as during intense exercise or overwork.
[0006] 生体内ュビキノール及びュビキノン含量の低下は、その特性上、 ATP産生力の減 退、心機能の減退、酸化ストレスに対する抵抗性の減退、生体膜の不安定化をもたら し、健康上好ましくない。不足しているュビキノール及びュビキノンを補給することは 、ミトコンドリアでのエネルギー産生促進及び生体の抗酸化能を向上し恒常性を維持 するために有益である。 [0006] Decreased contents of ubiquinol and ubiquinone in vivo lead to a decrease in ATP productivity, a decrease in cardiac function, a decrease in resistance to oxidative stress, and a destabilization of biological membranes. It is not preferable. Supplementing deficient ubiquinol and ubiquinone is beneficial for promoting energy production in mitochondria and improving the antioxidant capacity of the body and maintaining homeostasis.
[0007] ュビキノンには、例えば、心疾患、高血圧、肥満、糖尿病、癌、パーキンソン病、歯 周病、神経疾患、アレルギー、生殖能、運動能、免疫機能、疲労等の改善や予防の 効果が期待されている。 [0007] For example, ubiquinone has an effect of improving or preventing heart disease, hypertension, obesity, diabetes, cancer, Parkinson's disease, periodontal disease, neurological disease, allergy, fertility, motor ability, immune function, fatigue, etc. Expected.
[0008] 例えば、ュビキノン投与による心機能の亢進が報告されており(非特許文献 6)、ュ ビキノンによる鬱血性心不全、狭心症、心筋梗塞などの心疾患の改善効果 (非特許 文献 7、非特許文献 8)、動脈硬化、高血圧、糖尿病、癌、歯周病、アレルギーなどの 予防 ·改善効果 (非特許文献 9、非特許文献 10、非特許文献 11、非特許文献 12)、 生殖能向上効果、 LDLコレステロールの酸化抑制、腎透析患者での透析回数の減 少効果、非特異的免疫能の増強効果等が知られている (非特許文献 13、非特許文 献 14)。また、ュビキノンは既に、鬱血性心不全或いは軽度な心疾患による動悸、息 切れ、むくみの治療薬として利用されている。 [0008] For example, ubiquinone administration has been reported to increase cardiac function (Non-patent document 6), and ubiquinone has an effect to improve cardiac diseases such as congestive heart failure, angina pectoris, and myocardial infarction (Non-patent document 7, Non-patent document 8), prevention and improvement of arteriosclerosis, hypertension, diabetes, cancer, periodontal disease, allergy, etc. (Non-patent document 9, Non-patent document 10, Non-patent document 11, Non-patent document 12), Fertility It is known to have an improving effect, an inhibition of LDL cholesterol oxidation, an effect of reducing the number of dialysis in renal dialysis patients, and an effect of enhancing nonspecific immunity (Non-patent Document 13, Non-Patent Document 14). Ubiquinone is already used as a treatment for palpitations, shortness of breath, and swelling due to congestive heart failure or mild heart disease.
[0009] 日々の生活にお!/、て低下する生体内ュビキノール及びュビキノン含量を補うため は適度にュビキノールやュビキノンを補給することが必要である。中高年はもとより、 若い人でも、過度の運動時に指摘されるような酸化ストレス障害の場合は、特にュビ キノール含量が低下するので、ュビキノールを補給して生体の抗酸化能を上げてお くことは大切である。生体内のュビキノール含量を向上させるために、外来的にュビ キノンを補給する方法が従来より用いられてきた。 [0009] In order to compensate for the in vivo ubiquinol and ubiquinone contents that decrease in daily life !, it is necessary to appropriately supplement ubiquinol and ubiquinone. Even in middle-aged and young people, ubiquinol content decreases especially in the case of oxidative stress disorder that is pointed out during excessive exercise, so supplement ubiquinol to increase the antioxidant capacity of the living body. Is important. In order to improve the ubiquinol content in the living body, an exogenous method for supplementing ubiquinone has been used.
[0010] 上記の様に生体の機能維持に必要不可欠で、 日々の生活において減少 '不足し
力 Sちなュビキノンを補給する方法として、錠剤、カプセル剤の形態で医薬として、或 いはサプリメントとして補給する方法が既に実施されて!/、るが、不足の度合!/、が軽度 で医療の対象とならない健康人、或いは半健康人等にとって、錠剤やカプセル剤と して摂取するよりも、通常の食品と同様に摂取する方が簡便である。 [0010] As described above, it is indispensable for maintaining the functions of the living body, and it is decreasing and lacking in daily life. As a method of replenishing ubiquinone, a method of replenishing as a medicine or supplement in the form of tablets or capsules has already been implemented! / However, the degree of deficiency! / For healthy and semi-healthy people who are not the target, it is easier to ingest like normal foods than to ingest as tablets or capsules.
[0011] この様に、ュビキノンを含有した食品を利用すれば、生体内でュビキノンとュビキノ ールは平衡関係にあるので、ュビキノンそのものだけでなく不足しがちなュビキノー ルの補給が容易に可能になると考えられてきた。しかしながら、近年、種々の用途に ぉレ、て、ュビキノールを摂取することがュビキノンを摂取することよりも有効であるとの 報告がなされている。例えば、ュビキノールがュビキノンよりも経口吸収性に優れて いること(特許文献 1 )や、高コレステロール血症、高脂血症や動脈硬化症の改善'予 防に効果があること(特許文献 2)が報告されている。また、高齢者や病人ではュビキ ノンをュビキノールに還元する能力が弱くなるとの報告もある(非特許文献 15)。 [0011] In this way, if a food containing ubiquinone is used, ubiquinone and ubiquinol are in an equilibrium relationship in vivo, so it is possible to easily replenish not only ubiquinone itself but also ubiquinol, which tends to be insufficient. Has been considered to be. However, in recent years, it has been reported that taking ubiquinol is more effective than taking ubiquinone for various purposes. For example, ubiquinol has better oral absorption than ubiquinone (Patent Document 1), and is effective in preventing or preventing hypercholesterolemia, hyperlipidemia and arteriosclerosis (Patent Document 2). Has been reported. In addition, there is a report that the ability to reduce ubiquinone to ubiquinol is weakened in the elderly and sick (Non-patent Document 15).
[0012] このようにュビキノールを摂取することはその有用性が期待されている力 ュビキノ ールが非常に酸化されやすレ、とレ、う性質を有して!/、ることに加えて、ュビキノールそ のままでは吸収性が低ぐ吸収性を上げるためには油脂等に溶解し、さらに場合によ つては界面活性剤なども添加し、酸化を防ぐためにカプセル剤として摂取されるのが 一般的である。し力もながらカプセル剤の場合、高齢者や病人など嚥下能力の低い 人にとっては摂取しにくいと!/、う問題がある。 [0012] In addition to taking ubiquinol in this way, its strength is expected to be useful. In order to increase the absorption, ubiquinol as such is dissolved in oils and fats, and in some cases, surfactants are also added, and it is generally taken as a capsule to prevent oxidation. Is. However, in the case of capsules, they are difficult to take for people with low swallowing ability, such as the elderly and the sick!
[0013] またュビキノールを含有する食品として、ュビキノールを富化した油脂含有食品(特 許文献 3)が報告されている力 S、ここでは、脂溶性物質であるュビキノールを食品に含 有させるために、ュビキノールを油脂等に溶解あるいは共存させて使用している。 [0013] In addition, ubiquinol-enriched oil-and-fat-containing foods (Patent Document 3) have been reported as foods containing ubiquinol S, in order to include ubiquinol, a fat-soluble substance, in foods. , Ubiquinol is dissolved or coexisting in fats and oils.
[0014] 上述したように、ュビキノールの摂取においては、従来、油脂や界面活性剤などと 同時に摂取する方法が一般的である。油脂 (脂肪)は 3大栄養素の 1種であり、エネ ルギ一源として重要であると同時に、食品に対するなめらかな食感の付与、こくづけ 、濃厚感の付与等の機能を持つ。しかし、最近では肥満や生活習慣病への関心の 高まりから、食品中の高カロリー物質である脂肪の摂取量を低減化することが求めら れている。 [0014] As described above, in the intake of ubiquinol, conventionally, a method of taking in at the same time as fats and oils, surfactants, and the like is common. Oils and fats (fats) are one of the three macronutrients and are important as a source of energy, and at the same time have functions such as imparting a smooth texture to food, imparting richness, and so on. However, recently, with increasing interest in obesity and lifestyle-related diseases, it has been required to reduce the intake of fat, which is a high calorie substance in foods.
特許文献 1 :特開平 10— 109933
特許文献 2 :特開平 10— 330251 Patent Document 1: JP-A-10-109933 Patent Document 2: JP-A-10-330251
特許文献 3 : WO03/061395 Patent Document 3: WO03 / 061395
非特許文献 1 : Lipids, 24, 579-584 (1989) Non-Patent Document 1: Lipids, 24, 579-584 (1989)
非特許文献 2 : N印 hron, 66, 153-156 (1994) Non-Patent Document 2: N mark hron, 66, 153-156 (1994)
非特許文献 3 : BioFactors, 1, 303-306 (1988) Non-Patent Document 3: BioFactors, 1, 303-306 (1988)
非特許文献 4 : Atherosclerosis, 129, 119-126 (1997) Non-Patent Document 4: Atherosclerosis, 129, 119-126 (1997)
非特許文献 5: Clinical Investigator, 71, S97-S102 (1993) Non-Patent Document 5: Clinical Investigator, 71, S97-S102 (1993)
非特許文献 6: Clinical Investigator, 71, S71-S75 (1993) Non-Patent Document 6: Clinical Investigator, 71, S71-S75 (1993)
非特許文献 7 : Inter. J. Cardiology, 68, 23-29 (1999) Non-Patent Document 7: Inter. J. Cardiology, 68, 23-29 (1999)
非特許文献 8: Cardiovasc. Drugs Ther., 12, 347-353 (1998) Non-Patent Document 8: Cardiovasc. Drugs Ther., 12, 347-353 (1998)
非特許文献 9 : Atherosclerosis, 148, 275-282 (1999) Non-Patent Document 9: Atherosclerosis, 148, 275-282 (1999)
非特許文献 10 : Curr. Therap. Res., 51, 668-672 (1992) Non-Patent Document 10: Curr. Therap. Res., 51, 668-672 (1992)
非特許文献 11 :口腔衛生学会誌, 43, 667-672 (1993) Non-Patent Document 11: Journal of Oral Hygiene, 43, 667-672 (1993)
非特許文献 12 :臨床と研究, 58, 1349-1352(1981) Non-Patent Document 12: Clinical and Research, 58, 1349-1352 (1981)
非特許文献 13 : Mol. Aspects Med., 18, S85- S103 (1997) Non-Patent Document 13: Mol. Aspects Med., 18, S85-S103 (1997)
非特許文献 14 : Μο1· Aspects Med., 15, S213- S219 (1994)) (Non-Patent Document 14: Μο1 Aspects Med., 15, S213-S219 (1994))
非特許文献 15 : Acta Diabetol., 42, 179-181 (2005) Non-Patent Document 15: Acta Diabetol., 42, 179-181 (2005)
発明の開示 Disclosure of the invention
発明が解決しょうとする課題 Problems to be solved by the invention
[0015] 本発明の目的は、 日常生活で通常の食品と同様に摂取することにより、生体に必 要不可欠であるにも関わらず、減少 ·不足しがちなュビキノールを、健常な人はもとよ り高齢者や病人など嚥下能力の低下した人にとっても容易に且つ効率良く補給する ことができ、現代人の食生活で問題となって!/、るエネルギー過多に対しても好まし!/ヽ ゼリー状食品及びその用途を提供することにある。 [0015] The purpose of the present invention is to obtain ubiquinol, which is apt to be reduced or insufficient, in healthy people, even though it is indispensable for the living body by ingesting it in the same way as normal food in daily life. It can be replenished easily and efficiently even for people with lower swallowing ability, such as older people and sick people, and it is a problem in modern people's eating habits!あ る To provide jelly-like foods and their uses.
課題を解決するための手段 Means for solving the problem
[0016] 本発明者らは、油脂等に代えてゲル化剤を使用してゼリー状とすることにより、ュビ キノールを安定かつ均一に分散できてさらに吸収性にも優れたゼリー状食品となりう ることをはじめて見出した。そのようなゼリー状食品は、高齢者や病人など嚥下能力
の低下した人にとっても有用である。即ち、本発明は以下の通りである。 [0016] The present inventors use a gelling agent in place of fats and oils to make a jelly form, whereby ubiquinol can be stably and uniformly dispersed and a jelly-like food with excellent absorbability can be obtained. I found out for the first time. Such jelly-like foods are swallowing ability such as elderly and sick It is also useful for people who have fallen. That is, the present invention is as follows.
[0017] [1] ュビキノールを含有するゼリー状食品。 [0017] [1] A jelly-like food containing ubiquinol.
[2] ゼリー状とするためのゲル化剤を使用することを特徴とする [1]記載のゼリー状 ロ P〇 [2] A gelling agent for forming a jelly is used. The jelly described in [1]
[3] ゲル化剤として、寒天、ゼラチン、コンニヤク粉、ぺクチン、片栗でんぷん、葛で んぷん、蕨でんぷん(わらびこ)、タピオ力でんぷん及びカラギーナンからなる群より 選択される 1種以上のゲル化剤を使用することを特徴とする [1]又は [2]のゼリー状 [3] One or more gels selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan as a gelling agent [1] or [2] jelly, characterized by using an agent
^ PP o ^ PP o
[4] 粘度が 5.0 X 102—1.0 X 105 mPa' s、及び/又は、硬さが 5 X 104 N/m2以下で ある [1]〜 [3]レ、ずれかのゼリー状食品。 [4] Viscosity is 5.0 X 10 2 —1.0 X 10 5 mPa 's and / or hardness is 5 X 10 4 N / m 2 or less [1] to [3] Food.
[5] さらに有機酸を含有する [1]〜 [4] V、ずれかのゼリー状食品。 [5] Further containing an organic acid [1] to [4] V, any jelly-like food.
[6] さらに抗酸化剤を含有する [1]〜 [5] V、ずれかのゼリー状食品。 [6] Further containing an antioxidant [1] to [5] V, any jelly-like food.
[7] さらにビタミン類を含有する [1]〜 [6] V、ずれかのゼリー状食品。 [7] Further containing vitamins [1] to [6] V, some jelly-like food.
[8] 油脂の含有量が 0· 5重量%未満である [1]〜[7]いずれかのゼリー状食品。 発明の効果 [8] The jelly-like food according to any one of [1] to [7], wherein the fat content is less than 0.5% by weight. The invention's effect
[0018] 本発明のゼリー状食品は、 日常生活で通常の食品と同様に摂取することにより、生 体に必要不可欠であるにも関わらず、減少 ·不足しがちなュビキノールを、健常な人 はもとより高齢者や病人など嚥下能力の低下した人にとっても容易に且つ効率良く 補給することができるだけでなぐ現代人の食生活で問題となって!/、るエネルギー過 多に対しても好ましい低カロリーの食品である。 [0018] The jelly-like food of the present invention can be consumed in the same way as normal food in daily life. Of course, it is also a problem in the dietary habits of modern people who can easily and efficiently replenish even those with reduced swallowing ability such as elderly people and sick people! / Low calorie favorable for excessive energy Food.
発明を実施するための最良の形態 BEST MODE FOR CARRYING OUT THE INVENTION
[0019] 本発明のゼリー状食品は、ュビキノールを含有することを特徴とする。本発明のゼリ 一状食品において、含有されるュビキノールは、実質的にュビキノール単独であって もよく、又、ュビキノンとュビキノールの混合物であってもよい。本発明において、ュビ キノールとュビキノンの混合物を使用する場合、その割合は特に限定されないが、ュ ビキノールの含有量が高!/、ことが好まし!/、ことから、ュビキノール/ュビキノンの重量 比として、 40/60以上が好ましぐ 60/40以上がより好ましぐ 80/20がさらに好ま しぐ 95/5がよりさらに好ましぐ 99/1であるのがもっとも好ましい。
[0020] 本発明に使用するュビキノールは、合成法もしくは発酵法など、いかなる公知の方 法で製造されたものでもよいが、生体に対する安全性を慎重に配慮すれば、肉、魚 等の食品に含まれるものと同じ(aU-E)—異性体であるのが好ましぐこの場合、その 製造法が発酵法に由来するものが好ましい。ここで、「発酵法に由来する」とは、好ま しい上記立体異性が発酵法に基づき得られることを意味しており、例えば、発酵法に より得られた(aU-E)—異性体のュビキノン及び/又はュビキノールを、その立体を保 持したまま、酸化、還元等の処理により、所望の比率のュビキノールに変換することを 妨げない。尚、立体異性体は常法により HPLCにて分析される。 [0019] The jelly-like food of the present invention is characterized by containing ubiquinol. In the jelly-like food of the present invention, the ubiquinol contained may be substantially ubiquinol alone or a mixture of ubiquinone and ubiquinol. In the present invention, when a mixture of ubiquinol and ubiquinone is used, the ratio is not particularly limited, but it is preferable that the content of ubiquinol is high! /, So that the weight ratio of ubiquinol / ubiquinone. 40/60 or more is preferred 60/40 or more is more preferred 80/20 is more preferred 95/5 is more preferred 99/1 is most preferred. [0020] The ubiquinol used in the present invention may be produced by any known method such as a synthesis method or a fermentation method. However, if careful consideration is given to safety for living organisms, it can be used for foods such as meat and fish. Preferably the same (aU-E) -isomer as that contained, in which case the production method is preferably derived from the fermentation process. Here, “derived from the fermentation method” means that the preferred stereoisomerism is obtained based on the fermentation method, for example, the (aU-E) -isomer of the (aU-E) -isomer obtained by the fermentation method. It does not prevent the conversion of ubiquinone and / or ubiquinol into a desired ratio of ubiquinol by treatments such as oxidation and reduction while maintaining its solid form. Stereoisomers are analyzed by HPLC by a conventional method.
[0021] また、本発明に使用するュビキノールの製造は、常法で製造されたュビキノン、好 ましくは発酵法により製造されたュビキノンを、水素化ほう素ナトリウム、亜ジチオン酸 ナトリウム (ハイドロサルファイトナトリウム)、亜鉛等の一般的な還元剤を用いて、常法 により還元することにより行うこと力 Sできる。上記還元後は、晶析ゃクロマトグラフィー による濃縮を行っても良い。ュビキノールは、固体状であれ液状であれ、結晶状であ れ、アモルファス状であれ使用し得る。 [0021] In addition, ubiquinol used in the present invention is produced by using ubiquinone produced by a conventional method, preferably ubiquinone produced by fermentation, using sodium borohydride, sodium dithionite (hydrosulfite). This can be done by reducing by a conventional method using common reducing agents such as sodium) and zinc. After the reduction, crystallization may be concentrated by chromatography. Ubiquinol can be used whether it is solid, liquid, crystalline or amorphous.
[0022] ュビキノンとュビキノールの割合は、通常、 UV検出器を用いた HPLCシステムによ り、試料中のュビキノンとュビキノールを定量し、その量比をもって算出する方法、ま たは、 HPLCに電気化学的検出器を組み込んだシステムにより、ュビキノンとュビキ ノールの割合をピーク面積から算出する方法により求めることができる。電気化学的 検出器を組み込んだシステムでは、酸化還元物質を特異的に測れることおよび感度 が高!/、ことから、生体あるレ、は試料に微量に存在するュビキノールの割合を測定す る場合は、有用性が高い。具体的には、島津社製の HPLC分析装置に資生堂社製 の電気化学的検出器を組み込み、以下の HPLC条件で測定できる。 [0022] The ratio of ubiquinone and ubiquinol is usually determined by quantifying the amount of ubiquinone and ubiquinol in a sample by an HPLC system using a UV detector, and calculating the ratio of the amounts. Using a system incorporating a mechanical detector, the ratio of ubiquinone and ubiquinol can be determined from the peak area. In systems incorporating electrochemical detectors, redox substances can be specifically measured and the sensitivity is high! Therefore, when measuring the proportion of ubiquinol present in a sample in a very small amount, Highly useful. Specifically, it can be measured under the following HPLC conditions by incorporating an electrochemical detector manufactured by Shiseido Co., Ltd. into an Shimadzu HPLC analyzer.
[0023] カラム:丫^[じー?&。15(003—八303)、検出波長:2751 111、移動相:メタノール(8 8%)、へキサン(12%)、流速: lml/min。 [0023] Column: 丫 ^ [Ji? &. 1 5 (003—303), detection wavelength: 2751 111, mobile phase: methanol (88%), hexane (12%), flow rate: lml / min.
[0024] 本発明のゼリー状食品としては、いわゆるゲル状の形態を有する食品であれば特 に限定されないが、具体的には、ゼラチン、寒天、コンニヤクなどのゲル化剤によるゼ リーやゼリー寄せ、タピオ力、わらびもち、くず、ジャム、煮こごりなどが挙げられる。ま たこれらゲル状の組成物中に固形物を有しているものであってもかまわない。
[0025] 本発明のゼリー状食品に使用される材料としては、ゲル状の食品原料、または液状 の食品原料に適度な粘度を付加したものであれば特に限定されない。例えば、食品 として許容できるゲル化剤を使用して、必要であれば、加熱処理や加水などの処理 を行い、ゲル状、いわゆるゼリー状にすることによって、本発明のゼリー状食品を製造 すること力 Sでさる。 [0024] The jelly-like food of the present invention is not particularly limited as long as it is a food having a so-called gel-like form. Specifically, the jelly-like food is a jelly or a jelly-based food by a gelling agent such as gelatin, agar, or konjac. , Tapio power, warabimochi, litter, jam, boiled rice. Further, these gel-like compositions may have solids. [0025] The material used for the jelly-like food of the present invention is not particularly limited as long as it has an appropriate viscosity added to a gel food raw material or a liquid food raw material. For example, the jelly-like food of the present invention is produced by using a gelling agent that is acceptable as a food and, if necessary, heat treatment or addition of water to form a gel or so-called jelly. Touch with force S.
[0026] 本発明に用いられるゲル化剤としては特に限定されず、とうもろこしでんぷん、片栗 でんぷん、馬鈴薯でんぷん、さつまいもでんぷん、葛でんぷん、蕨でんぷん(わらび こ)、タピオ力でんぷん、などのでんぷん類、寒天、ゼラチン、コンニヤク粉(ダルコマ ンナン、ガラタトマンナン)、ぺクチン、カラギーナン、アルギン酸及びその塩、サイリウ ム、アラビアガム、ローカストビーンガム、グァーガム、タマリンドガム、クィンスシードガ ム、カラャガム、トラガントガム、ガッティ一ガム、キサンタンガム、ジエランガム(ネィテ ィブジエランガム、脱ァシル型ジエランガム)、タラガム、ァラビノガラタタン、ファーセレ ラン、マノレメロ、カードラン、プノレラン、デキストラン、カノレポキシメチノレセノレロースナトリ ゥム等のセルロース誘導体等が挙げられる。好ましくは、でんぷん類、寒天、ゼラチン 、コンニヤク粉、ぺクチンである。より好ましくは、寒天、ゼラチン、コンニヤク粉、ぺクチ ン、片栗でんぷん、葛でんぷん、蕨でんぷん(わらびこ)、タピオ力でんぷんである。こ れらのゲル化剤は 2種以上組み合わせても力、まわない。 [0026] The gelling agent used in the present invention is not particularly limited, and corn starch, potato starch, potato starch, sweet potato starch, katsu starch, potato starch (warabiko), tapio force starch, and other starches, agar , Gelatin, konjac flour (Darkmananan, galatatomannan), pectin, carrageenan, alginic acid and its salts, sirium, gum arabic, locust bean gum, guar gum, tamarind gum, quince seed gum, cara gum, tragacanth gum, gati gum, Xanthan gum, dielan gum (native dielan gum, deacyl type dielan gum), tara gum, arabinogalatatan, fur celerin, manolemero, curdlan, punoreran, dextran, canolepoxy methylenoresenorelona And cellulose derivatives such as Li ©-time, and the like. Starches, agar, gelatin, konjac flour, and pectin are preferable. More preferred are agar, gelatin, konjac flour, pectin, kataguri starch, katsu starch, bran starch, tapio force starch. Two or more of these gelling agents do not work.
[0027] 本発明のゼリー状食品は、弾性のある半固体の、いわゆるゼリーやゼリー状飲料に 類する形状や物性を有しているものであれば特に限定されないが、例えば、その粘 度としては、摂取時の温度条件下で、 5.0 X 102 mPa' s以上の粘性を有するのが好ま しぐまたその上限としては 1.0 X 105 mPa' s以下であるのが好ましい。硬さとしては、 6 X 104 N/m2以下の硬さが好ましぐ 5 X 104 N/m2以下であるのがさらに好ましい。 [0027] The jelly-like food of the present invention is not particularly limited as long as it has a shape and physical properties similar to an elastic semi-solid, so-called jelly or jelly-like beverage. It is preferable to have a viscosity of 5.0 × 10 2 mPa ′s or more under the temperature condition at the time of ingestion, and the upper limit thereof is preferably 1.0 × 10 5 mPa ′s or less. The hardness is more preferably 5 × 10 4 N / m 2 or less, which is preferably 6 × 10 4 N / m 2 or less.
[0028] ここでいう粘度とは、「液体の流れ難さ、あるいは粘っこさの程度を示す物質定数」 で、これを粘性率あるいは粘度という。力を加えて流したときに、内部に摩擦を生じて 止まっていぐすなわち、押し流す力に抵抗する性質を粘性という。 The term “viscosity” as used herein means “a material constant indicating the difficulty of liquid flow or the degree of viscosity”, which is referred to as viscosity or viscosity. Viscosity is the property that resists the force of squeezing when friction is applied to the inside when it is applied.
[0029] ここでいう硬さとは、「一定速度で圧縮したときの抵抗」で、物質に外部から局部的 な力(集中荷重)を短時間に加えて、そのときに示される物質の変形度合力 変形に 対する抵抗の大小を判断してこれを硬さとしている。
[0030] 食品の粘度や硬さは、市販の粘度計(レオメーター、クリープメーター等)を用いて 測ることが出来る。 [0029] Hardness here refers to "resistance when compressed at a constant speed". When a local force (concentrated load) is applied to a substance from outside in a short time, the degree of deformation of the substance indicated at that time is shown. The strength of the resistance against the resultant deformation is determined as hardness. [0030] The viscosity and hardness of food can be measured using a commercially available viscometer (rheometer, creep meter, etc.).
[0031] さらに、本発明におけるゼリー状食品は、嚥下障害者向けの食品、栄養補助食品と しても使用すること力できる。高齢社会において、寝たきり'重度の痴呆'脳卒中後遺 症等、運動障害のある高齢者数も増加している。嚥下機能が障害されると、食物や 飲料を正常に飲み込めず、誤って気管に引き込んでしまう誤嚥 (ごえん)によって、窒 息死や誤嚥性肺炎の誘発と!/、つた危険性もある。健常者では水の様に低粘度の液 体がもっとも飲み込み易いが、嚥下困難者においてはとろみのある方がかえって誤 嚥を起こしにくいことが知られ、病院、特養ホーム等では液状食品に粘性を加えた食 品が用いられている。また、当然食材の硬さも重要であり、ある程度の柔らかさでない と、嚙み砕いたり、飲み混んだりすることが難しくなる。 [0031] Furthermore, the jelly-like food according to the present invention can be used as a food for dysphagia and as a dietary supplement. In an aging society, the number of elderly people with movement disorders such as bedridden 'severe dementia' and sequelae of stroke is increasing. If the swallowing function is impaired, food and beverages cannot be swallowed normally, and aspiration that is accidentally drawn into the trachea can lead to death of asphyxia and aspiration pneumonia! is there. It is known that a liquid with a low viscosity like water is most easily swallowed by healthy people, but it is known that a person who has difficulty swallowing is less likely to cause aspiration. Food is used. Naturally, the hardness of the food is also important, and if it is not soft enough, it will be difficult to knead and mix.
[0032] 日本厚生労働省では、粘度が 1.5 X 103 mPa' s以上、硬さ力 X 104 N/m2以下(舌 でつぶせる程度の硬さ)のものを、咀嚼 '嚥下困難者用食品の基準としていることから 、本発明のゼリー状食品を、これら基準を満たすように調整することによって、咀嚼- 嚥下困難者用食品として使用することが可能である。また、このようなゼリー状食品は 、幼児 ·老人向け食品用途にも好ましく利用できる。 [0032] According to the Ministry of Health, Labor and Welfare, foods with a viscosity of 1.5 X 10 3 mPa 's or more and a hardness force of 10 4 N / m 2 or less (hard enough to be crushed by the tongue) Therefore, by adjusting the jelly-like food of the present invention so as to satisfy these standards, it can be used as a food for persons with difficulty in chewing-swallowing. Moreover, such jelly-like food can be preferably used for food use for infants and the elderly.
[0033] 本発明のゼリー状食品において、 目的とする粘度や硬度に調整する方法としては 特に限定されず、ゲル化剤の種類や使用量を調整したり、適宜その他増粘剤などを 使用するなど公知の方法を用いることができる。また、咀嚼'嚥下困難者用食品用途 に適した粘度と硬さのゼリー状食品とするためには、例えば、ゲル化剤としてゼラチン と、寒天またはカラギーナンを併用する、あるいは、カラギーナンとキサンタンガムま たはネイティブジエランガムを併用するなどの方法が挙げられる。 [0033] In the jelly-like food of the present invention, the method for adjusting to the target viscosity and hardness is not particularly limited, and the type and amount of the gelling agent are adjusted, and other thickeners are used as appropriate. For example, a known method can be used. In addition, in order to make a jelly-like food with viscosity and hardness suitable for food use for chewing and difficult to swallow, for example, gelatin and agar or carrageenan are used as a gelling agent, or carrageenan and xanthan gum are used. The method includes using native dielan gum in combination.
[0034] 本発明のゼリー状食品には、抗酸化剤、有機酸、ビタミン類を添加しても良い。 [0034] An antioxidant, an organic acid, and vitamins may be added to the jelly-like food of the present invention.
[0035] 抗酸化剤としては、リコペン、カロテノイド類、フラボノイド類、ポリフエノール類、ダル タチオン、セレン、チォ硫酸ナトリウム、 αリポ酸およびその誘導体、ピクノジェノール 、フラバンジェノール、スーパーオキサイドデイスムターゼ(SOD)、グルタチオンペル ォキシダーゼ、ダルタチオン S トランスフェラーゼ、ダルタチオン還元酵素、力タラ ーゼ、ァスコルビン酸ペルォキシダーゼ、およびこれらの混合物などが挙げられる。こ
れら抗酸化剤はュビキノールの酸化に対する安定性を高め、より安定した高い効果 を得る観点から特に好ましい添加物として使用される。 [0035] Antioxidants include lycopene, carotenoids, flavonoids, polyphenols, dartathione, selenium, sodium thiosulfate, alpha lipoic acid and its derivatives, pycnogenol, flavangenol, superoxide dismutase (SOD) Glutathione peroxidase, dartathione S transferase, dartathione reductase, force tarase, ascorbate peroxidase, and mixtures thereof. This These antioxidants are used as particularly preferred additives from the viewpoint of enhancing the stability of ubiquinol to oxidation and obtaining a more stable and high effect.
[0036] 有機酸としては、特に限定はされないが、例えば、クェン酸、クェン酸誘導体、酢酸 、乳酸、コハク酸、酒石酸、ァスパラギン酸、シユウ酸、リンゴ酸、マロン酸、フマル酸、 マレイン酸、プロピオン酸、酪酸、バレリン酸、イソクェン酸、およびこれらの混合物な ど力 S挙げられる。有機酸はそれ自体が体に有用な成分であるだけでなぐ本発明の ゼリー状食品に適度な風味を付加できる点で好ましい。 [0036] The organic acid is not particularly limited, but examples thereof include succinic acid, succinic acid derivatives, acetic acid, lactic acid, succinic acid, tartaric acid, aspartic acid, oxalic acid, malic acid, malonic acid, fumaric acid, maleic acid, Examples include propionic acid, butyric acid, valeric acid, isochenoic acid, and mixtures thereof. Organic acids are preferred in that they can add an appropriate flavor to the jelly-like food of the present invention, which is not only a component useful for the body itself.
[0037] ビタミン類としては特に限定されず、例えば、ビタミン A、ビタミン B (ビタミン Bl、ビタ ミン B1誘導体、ビタミン B2、ビタミン B6、ビタミン B12など)、ビタミン C、ビタミン D、ビ タミン£、ビタミン 、ビォチン、パントテン酸、ニコチン酸、およびこれらの混合物など が挙げられる。ここで、ビタミン B1誘導体には、チアミンまたはその塩、チアミンジスル フイド、フルスルチアミンまたはその塩、ジセチアミン、ビスブチチアミン、ビスベンチア ミン、ベンフォチアミン、チアミンモノフォスフェートジスルフイド、シコチアミン、オタトチ ァミン、プロスルチアミンなどのビタミン B1としての生理活性を有する化合物のすべて が含まれ得る。 [0037] The vitamins are not particularly limited. For example, vitamin A, vitamin B (vitamin Bl, vitamin B1 derivative, vitamin B2, vitamin B6, vitamin B12, etc.), vitamin C, vitamin D, vitamins, vitamins , Biotin, pantothenic acid, nicotinic acid, and mixtures thereof. Here, the vitamin B1 derivative includes thiamine or a salt thereof, thiamine disulfide, fursultiamine or a salt thereof, dicetiamine, bisbuthiamine, bisbentiamine, benfotiamine, thiamine monophosphate disulfide, chicotiamine, otato thiamine, All of the compounds having physiological activity as vitamin B1, such as prosultiamine, can be included.
[0038] これらの抗酸化物質、有機酸、ビタミン類は、 2種類以上を組み合わせても良い。 [0038] These antioxidants, organic acids, and vitamins may be used in combination of two or more.
[0039] 本発明のゼリー状食品に含まれる他の成分としては、食品に使用できる成分であ れば特に限定されず、必要に応じて、糖類、甘味料、果汁、フレーバー粉末、香料、 防腐剤、着色剤や保存剤などが使用できる。 [0039] Other ingredients contained in the jelly-like food of the present invention are not particularly limited as long as they are ingredients that can be used in foods. If necessary, sugars, sweeteners, fruit juices, flavor powders, flavors, antiseptics Agents, colorants, preservatives, etc. can be used.
[0040] 糖類としては特に限定されず、例えば、庶糖、ブドウ糖、果糖、乳糖、麦芽糖、異性 化糖、カップリングシュガー、パラチノース、ネオシュガー、還元澱粉糖化飴、キシロ ース、ソルボース、ラクッロース、ポリデキストロース等の水溶性糖類、およびこれらの 混合物などが挙げられる。 [0040] The saccharide is not particularly limited, and examples thereof include sucrose, glucose, fructose, lactose, maltose, isomerized sugar, coupling sugar, palatinose, neosugar, reduced starch saccharified starch, xylose, sorbose, lactulose, poly And water-soluble saccharides such as dextrose, and mixtures thereof.
[0041] 甘味料としては特に限定されず、例えば、サッカリンナトリウム、アスパルテーム、ス テビォサイド、ステビアエキス、パラメトキシシンナミックアルデヒド、ネオヘスペリジル ジヒドロカルコン、ペリラルチン、およびこれらの混合物などが挙げられる。 [0041] The sweetener is not particularly limited, and examples thereof include saccharin sodium, aspartame, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartin, and mixtures thereof.
[0042] 果汁としては特に限定されず、例えば、りんご果汁、オレンジ果汁、ぶどう果汁、メロ ン果汁、レモン果汁などが用いられる。
[0043] フレーバー粉末としては特に限定されず、例えば、コーヒー粉末、抹茶粉末、煎茶 粉末、ココア粉末などが用いられる。 [0042] The fruit juice is not particularly limited, and examples thereof include apple juice, orange juice, grape juice, melon juice, lemon juice and the like. [0043] The flavor powder is not particularly limited, and for example, coffee powder, matcha powder, sencha powder, cocoa powder and the like are used.
[0044] 香料としては特に限定されず、例えば、メントール、カルボン、ァネトール、シネオ一 ル、サリチル酸メチル、シンナミックアルデヒド、オイゲノール、 3 (1ーメントキシ)プ ロノ ンー 1 , 2—ジォ一ノレ、チモーノレ、リナローノレ、リナリーノレアセテート、 リモネン、メ ントン、メンチルアセテート、 N—置換 パラメンタン一 3—カルボキサミド、ビネン、ォ クチノレァノレデヒド、シトラール、プレゴン、カルビールアセテート、ァニスアルデヒド、ェ チルアセテート、ェチルブチレート、ァリルシクロへキサンプロピオネート、メチルアン スラニレート、ェチノレメチノレエチニノレグリシデート、ノ ニリン、ゥンデカラクトン、へキサ ナーノレ、 ェチノレアノレコーノレ、プロピノレアノレコーノレ、ブタノーノレ、イソアミノレァノレコーノレ 、へキセノール、ジメチルサルファイド、シクロテン、フルフラール、トリメチルビラゾン、 ェチルラタテート、ェチルチオアセテートなどの単品香料、更に、ペパーミント油、ス ペアミント油、ァニス油、ユーカリ油、ウィンターグリーン油、カシア油、クローブ油、タ ィム油、セージ油、レモン油、オレンジ油、ハツ力油、カルダモン油、コリアンダー油、 マンダリン油、ライム油、ラベンダー油、ローズマリー油、ローレノレ油、力モミ一ノレ油、 キャラウェイ油、マジョラム油、べィ油、レモングラス油、ォリガナム油、パインニードル 油、ネロリ油、ローズ油、ジャスミン油、イリスコンクリート、アブソリユートペパーミント、 アブソリュートローズ、オレンジフラワーなどの天然香料、ストロベリーフレーバー、ァ ップノレフレーノ一、ノ ナナフレーノ一、ノ ィナップノレフレーノ一、グレープフレーノ 一、マンゴーフレーノ一、ノ ターフレーノ一. ミノレ々フレーノ一、フノレーッミックスフレ 一バー、トロピカルフルーツフレーバーなどの調合香料、およびこれらの混合物など が挙げられる。 [0044] The fragrance is not particularly limited, and examples thereof include menthol, carvone, vanetol, cineol, methyl salicylate, cinnamic aldehyde, eugenol, 3 (1-menthoxy) pronone 1, 2-dionole, and chimole. , Linalool, linalino acetate, limonene, menton, menthyl acetate, N-substituted paramentan 1-carboxamide, vinylene, octanolenodehydride, citral, pregon, carbyl acetate, anisaldehyde, ethyl acetate, ethyl butyrate , Allylcyclohexanepropionate, methylanthranilate, ethinoremethinoreethino glycidate, nonylin, undecalactone, hexananol, ethinoreanoreconole, propinoreanoreconole, butanol Single-flavored products such as soaminoleanolecole, hexenol, dimethylsulfide, cycloten, furfural, trimethylvirazone, ethyllatatate, ethylthioacetate, peppermint oil, spearmint oil, anise oil, eucalyptus oil, wintergreen oil , Cassia oil, Clove oil, Time oil, Sage oil, Lemon oil, Orange oil, Heart force oil, Cardamom oil, Coriander oil, Mandarin oil, Lime oil, Lavender oil, Rosemary oil, Lorenole oil, Power fir Natural oil such as oil, caraway oil, marjoram oil, bay oil, lemongrass oil, oliganum oil, pine needle oil, neroli oil, rose oil, jasmine oil, Iris concrete, absolute peppermint, absolute rose, orange flower Fragrance, straw Believe Flavor, Ap Nore Freno, Nonana Freno, Nonap No Le Freno, Grape Freno, Mango Freno, Notter Flano. Minore Le Freno, Funolex Mix Flavor, Tropical Fruit Flavor, etc. Fragrances, and mixtures thereof.
[0045] 防腐剤としては特に限定されず、例えば、アミノエチルスルホン酸、安息香酸、安息 香酸ナトリウム、エタノール、ェデト酸ナトリウム、カンテン、 dl—カンフル、クェン酸、ク ェン酸ナトリウム、サリチル酸、サリチル酸ナトリウム、サリチル酸フエニル、ジブチルヒ ドロキシトルエン、ソルビン酸、ソルビン酸カリウム、窒素、デヒドロ酢酸、デヒドロ酢酸 ナトリウム、 2—ナフトール、 白糖、ハチミツ、パラォキシ安息香酸イソブチル、パラオ キシ安息香酸イソプロピル、パラォキシ安息香酸ェチル、パラォキシ安息香酸ブチル
、パラォキシ安息香酸プロピル、パラォキシ安息香酸メチル、 1 メントール、ユーカリ 油、およびこれらの混合物などが挙げられる。 [0045] The preservative is not particularly limited, and examples thereof include aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citrate, sodium citrate, salicylic acid, Sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid, potassium sorbate, nitrogen, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate , Butyl paraoxybenzoate Propyl parabenzoate, methyl paraoxybenzoate, 1 menthol, eucalyptus oil, and mixtures thereof.
[0046] 着色剤としては特に限定されず、食品に添加することが許可されているものなどを 使用すること力でき、例えば、青色 1号、黄色 4号、緑色 3号、赤色 5号、レーキ色素、 二酸化チタン、赤キャベツ色素、紅麹色素、ムラサキイモ色素、クチナシ色素、コチニ ール色素、カラメル色素、クロロフィル、およびこれらの混合物などが挙げられる。 [0046] The colorant is not particularly limited, and it is possible to use one that is permitted to be added to food, for example, Blue No. 1, Yellow No. 4, Green No. 3, Red No. 5, Lake Examples thereof include dyes, titanium dioxide, red cabbage dyes, red potato dyes, purple potato dyes, gardenia dyes, cochineal dyes, caramel dyes, chlorophylls, and mixtures thereof.
[0047] 保存剤としては特に限定されず、例えば、安息香酸、安息香酸ナトリウム、エタノー ノレ、ェデト酸ナトリウム、乾燥亜硫酸ナトリウム、クェン酸、グリセリン、サリチル酸、サリ チル酸ナトリウム、ジブチルヒドロキシトルエン、 D ソルビトール、ソルビン酸、ソルビ ン酸カリウム、デヒドロ酢酸ナトリウム、ノ ラオキシ安息香酸イソプチル、ノ ラオキシ安 息香酸イソプロピル、パラォキシ安息香酸ェチル、パラォキシ安息香酸ブチル、パラ ォキシ安息香酸プロピル、パラォキシ安息香酸メチル、プロピレングリコール、リン酸 、およびこれらの混合物などが挙げられる。 [0047] The preservative is not particularly limited. For example, benzoic acid, sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citrate, glycerin, salicylic acid, sodium salicylate, dibutylhydroxytoluene, D sorbitol , Sorbic acid, potassium sorbate, sodium dehydroacetate, isoptyl noroxybenzoate, isopropyl noroxybenzoate, ethyl parabenzoate, butyl parabenzoate, propyl parabenzoate, methyl paraoxybenzoate, propylene glycol , Phosphoric acid, and mixtures thereof.
[0048] また、本発明のゼリー状食品には、若干量の油脂成分を含んでいてもかまわない [0048] The jelly-like food of the present invention may contain a slight amount of fat and oil components.
1S カロリーを低く抑えるという目的の場合はその使用量は少ないほど好ましぐその 観点からは油脂の使用量は、食品全体量に対し 10重量%以下であるのが好ましぐ 5重量%以下であるのがより好ましぐ 1重量%以下であるのがさらに好ましぐ 0. 5重 量%未満であるのが特に好ましい。通常、一般食品やサプリメントにおいて、ュビキノ 一ルを製剤や食品中に可溶化あるいは分散させるために、ュビキノールよりも大過剰 量の油脂が使用される力 本発明のゼリー状食品においては、ゼリー状とすることで 好適にュビキノールを食品中分散させることが可能なため、食品中のュビキノールに 対する油脂の含有量を例えば等量以下、さらには半分以下とすることもでき、油脂を 実質的にあるレヽはまったく含まな!/、ことも可能である。 For the purpose of keeping 1S calorie low, the less the amount used, the better. From the viewpoint, the amount of fat used is preferably 10% by weight or less, and preferably 5% by weight or less, based on the total amount of food. More preferably, it is 1% by weight or less, more preferably less than 0.5% by weight. In general foods and supplements, the ability to use a larger excess of oil than ubiquinol in order to solubilize or disperse ubiquinol in pharmaceutical preparations and foods. Thus, ubiquinol can be suitably dispersed in the food, so that the content of fat and oil relative to ubiquinol in the food can be, for example, equal or less, and even less than half. Is not included at all!
[0049] 本発明のゼリー状食品は、一般食品として、また栄養補助食品、健康食品として、 健常者のみならず、高齢者や何らかの疾患を有している病人に、ュビキノールを補 給しうる低カロリー食品として摂取できる。さらには、また、嚥下障害を有する高齢者 や病人に対する補助食品としても有用である。さらには、従来のカプセル摂取が困難 であったペットなどの動物への応用も可能である。その形態としては、例えばカップ等
に装填されたゼリーとして、あるいはバウチ等に充填されたゼリー状飲料として提供さ れる他、使用者側で加水及び/又は加熱などの調理を行うことで、ゼリー状とするこ とができる粉末 ·固形形態として提供される。 [0049] The jelly-like food of the present invention is a general food, as a dietary supplement and a health food, and is low in ubiquinol for not only healthy subjects but also elderly people and sick people with some disease. Can be consumed as a calorie food. Furthermore, it is also useful as a supplement for elderly and sick people with dysphagia. Furthermore, it can also be applied to animals such as pets, which have been difficult to consume in the past. As its form, for example, a cup or the like In addition to being provided as a jelly loaded in a bag or as a jelly-like beverage filled in a bouch or the like, the user can also prepare a jelly-like powder by cooking such as water and / or heating. Provided as a solid form.
[0050] 本発明のゼリー状食品の摂取量としては特に限定されないが、成人 1日あたり、ュ ビキノーノレ量として lmg〜; !OOOmg、好ましくは 10mg〜500mg、さらに好ましくは 3 0mg〜300mgでめる。 [0050] The amount of the jelly-like food of the present invention is not particularly limited, but the daily dose for adults is lmg to;! OOOmg, preferably 10mg to 500mg, more preferably 30mg to 300mg. .
実施例 Example
[0051] 以下に実施例を揚げて本発明を更に詳しく説明するが、本発明はこれら実施例の みに限定されるものではない。尚、純度及びュビキノール/ュビキノンの比率(重量 比)は上記 HPLC分析により求めた。 [0051] Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples. The purity and the ubiquinol / ubiquinone ratio (weight ratio) were determined by the above HPLC analysis.
[0052] (製造例 1 )ュビキノールの製造 [0052] (Production Example 1) Production of ubiquinol
lOOOgのエタノーノレ中 ίこ、 lOOgのュヒ、、キノン(純度 99. 4%) , 60gの L ァスコノレ ビン酸を加え、 78°Cにて攪拌し、還元反応を行った。 30時間後、 50°Cまで冷却し、 同温を保持しながらエタノール 330gと水 70gを添加した。このエタノール溶液(ュビ キノール lOOgを含む)を攪拌しながら、 10°C/時間の冷却速度で 2°Cまで冷却し、 白色のスラリーを得た。得られたスラリーを減圧濾過し、湿結晶を冷エタノール、冷水 、冷エタノールで順に洗浄 (洗浄に用いた冷溶媒の温度は 2°C)して、さらに湿結晶 を減圧乾燥(20〜40°C、;!〜 30mmHg)することにより、白色の乾燥結晶 97gを得た 。減圧乾燥を除く全ての操作は窒素雰囲気下で実施した。 A lOOOOg ethanol solution, lOOg liquor, quinone (purity 99.4%) and 60 g L-asconolevic acid were added, and the mixture was stirred at 78 ° C. to carry out a reduction reaction. After 30 hours, the mixture was cooled to 50 ° C, and 330 g of ethanol and 70 g of water were added while maintaining the same temperature. While stirring this ethanol solution (containing ubiquinol lOOg), it was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to obtain a white slurry. The obtained slurry was filtered under reduced pressure, and the wet crystals were washed with cold ethanol, cold water and cold ethanol in this order (the temperature of the cold solvent used for washing was 2 ° C), and the wet crystals were further dried under reduced pressure (20-40 ° C). C,;! To 30 mmHg) to obtain 97 g of white dry crystals. All operations except drying under reduced pressure were performed under a nitrogen atmosphere.
[0053] (製造例 2)ュビキノールの製造 [Production Example 2] Production of ubiquinol
lOOgのュビキノン(純度 99. 4%)を 25°Cで lOOOgのヘプタン溶液に溶解させた。 攪拌しながら、還元剤として次亜硫酸ナトリウム(純度 75%以上) lOOgに 1000mlの 水を加えて溶解させた水溶液を徐々に添加し、 25°C、 pH4〜6で還元反応を行った 。 2時間後、反応液から水相を除去し、脱気した飽和食塩水 lOOOgでヘプタン相を 6 回水洗した。以上、すべての操作は窒素雰囲気下で実施した。このヘプタン相を減 圧下にて溶媒置換し、 50°Cのュビキノールの 7% (w/w)エタノール溶液を調製した (ュビキノールを lOOg含む)。このエタノール溶液に水 50gを添カロし、攪拌しながら、 10°C/時間の冷却速度で 2°Cまで冷却して結晶を析出させた。全ての操作は窒素
雰囲気下で実施した。得られたスラリーを減圧濾過し、湿結晶を冷エタノール、冷水lOOg ubiquinone (purity 99.4%) was dissolved in lOOOg heptane solution at 25 ° C. While stirring, sodium hyposulfite (purity of 75% or more) as a reducing agent was gradually added an aqueous solution prepared by adding 1000 ml of water to lOOg, and a reduction reaction was performed at 25 ° C and pH 4-6. After 2 hours, the aqueous phase was removed from the reaction solution, and the heptane phase was washed 6 times with degassed saturated saline lOOOg. As described above, all operations were performed in a nitrogen atmosphere. This heptane phase was subjected to solvent replacement under reduced pressure to prepare a 7% (w / w) ethanol solution of ubiquinol at 50 ° C (containing lOOg of ubiquinol). 50 g of water was added to the ethanol solution, and while stirring, the solution was cooled to 2 ° C. at a cooling rate of 10 ° C./hour to precipitate crystals. All operations are nitrogen Performed under atmosphere. The obtained slurry was filtered under reduced pressure, and the wet crystals were cooled with cold ethanol and cold water.
、冷エタノールで順に洗浄 (洗浄に用いた冷溶媒の温度は 2°C)して、さらに、湿結晶 を減圧乾燥(20〜40°C、;!〜 30mmHg)することにより、白色の乾燥結晶 97gを得たNext, wash with cold ethanol (the temperature of the cold solvent used for washing is 2 ° C), and dry the wet crystals under reduced pressure (20-40 ° C;! -30mmHg) to obtain white dry crystals. Obtained 97g
〇 Yes
[0054] (実施例 1 )ゼリー状食品の製造 [Example 1] Production of jelly-like food
400gの水にゼラチン(新田ゼラチン株式会社製;タイプ R) 20gを加え、 70°Cにて ゼラチンを溶解させた。同温を維持しながら、製造例 1で得られた 5gのュビキノール を加え、ュビキノールが完全に融解した後、 TKホモミキサー MarkII2. 5型(プライミ タス株式会社製)を用い、 5分間(lOOOOrpm)乳化させた。この乳化液を室温まで冷 却させた後、さらに、冷蔵庫 (4°C)にて 2時間冷却することにより、ュビキノールを含 有するゼリーを調製した。得られたゼリーは均一で、ゼリー中ュビキノールが析出す ることなく良好に分散していた。 20 g of gelatin (Nitta Gelatin Co., Ltd .; type R) was added to 400 g of water, and gelatin was dissolved at 70 ° C. While maintaining the same temperature, add 5 g of ubiquinol obtained in Production Example 1 and completely melt the ubiquinol, then use TK homomixer MarkII2.5 type 5 (manufactured by Primitas Co., Ltd.) for 5 minutes (lOOOOrpm) Emulsified. After cooling this emulsion to room temperature, it was further cooled in a refrigerator (4 ° C.) for 2 hours to prepare a jelly containing ubiquinol. The obtained jelly was uniform and dispersed well without precipitation of ubiquinol in the jelly.
<サンプル調製〉 <Sample preparation>
動物試験のため、ュビキノールを含有するゼリー状食品を乾燥させたモデルサンプ ルを以下のようにして調製した。 For animal testing, a model sample obtained by drying a jelly-like food containing ubiquinol was prepared as follows.
[0056] 160gの蒸留水に、ゼラチン(新田ゼラチン株式会社製; APH— 250) 40gを 60°C で溶解させ、ゼラチン水溶液を作成した。この水溶液を 60°Cに加温後、上記製造例 1で得られたュビキノール粉末 6. 2gを添加して溶融させた後、 TKホモミキサー Mar kll (プライミクス株式会社製)で 10000回転 X 5分間乳化し、水中油型乳化組成物を 得た。ここで得た水中油型乳化組成物 75gを、あらかじめ 90°Cに加熱しておいた、 M CT (理研ビタミン社製;アクター M— 2) 145gおよび界面活性剤(ポリグリセリン縮合リ シノール酸エステル:阪本薬品工業株式会社製; SYグリスター CRS— 75) 5gからな る油性成分に添加し、攪拌及び懸濁液の温度を 105°Cに調整することで、水分を蒸 発させた。その後は、常法に従って、固液分離により油性成分をろ別し、約 500gの エタノールで粒子に付着した油性成分を洗浄 ·除去後、 50°Cで乾燥して、ュビキノー ルがゼラチン中に分散した粒子状組成物(ゼリー状食品のモデルサンプル)を得た。 この組成物および製造例 1のュビキノール結晶(粉末そのまま)を、それぞれラット用
カプセルに詰めて評価サンプルとした。 [0056] In 160 g of distilled water, 40 g of gelatin (manufactured by Nitta Gelatin Co., Ltd .; APH-250) was dissolved at 60 ° C to prepare an aqueous gelatin solution. After heating this aqueous solution to 60 ° C, 6.2 g of the ubiquinol powder obtained in Production Example 1 above was added and melted, and then 10000 rotations x 5 minutes with TK homomixer Mar kll (manufactured by Primics Co., Ltd.) Emulsification was performed to obtain an oil-in-water emulsion composition. 75 g of the oil-in-water emulsion composition obtained here was heated to 90 ° C in advance, 145 g of M CT (manufactured by Riken Vitamin Co., Ltd .; Actor M-2) and surfactant (polyglycerin condensed ricinoleic acid ester) : Sakamoto Yakuhin Kogyo Co., Ltd .; SY Glyster CRS-75) Water was evaporated by adding to 5 g of oil component and adjusting the temperature of stirring and suspension to 105 ° C. After that, oily components are separated by solid-liquid separation according to a conventional method, and the oily components adhering to the particles are washed and removed with about 500 g of ethanol, dried at 50 ° C, and ubiquinol is dispersed in gelatin. A particulate composition (model sample of jelly-like food) was obtained. This composition and the ubiquinol crystals of Production Example 1 (as powders) were used for rats respectively. An evaluation sample was packed in a capsule.
[0057] <実験系〉 [0057] <Experimental system>
8週齢の雄性 Sprague— Dawleyラット(ブリーダーまたは入手元:日本エスエルシ 一株式会社)に上記に記載の被験物質をュビキノールとして 10mg/kgの用量で、 カプセル用ゾンデを用いて経口投与した(各サンプル N= 5)。被験物質投与 1、 2、 4 、 8、および 24時間後に各ラットより血液を採取した。採取した血液を遠心分離し、血 漿を得た。その後、血漿中のュビキノールの酸化処理、およびュビキノンの抽出処理 を行い、 HPLCを用いてュビキノンの濃度を測定した。 8-week-old male Sprague-Dawley rats (Bleeder or source: Nippon SLC Co., Ltd.) were orally administered with the test substance described above as ubiquinol at a dose of 10 mg / kg using a capsule sonde (each sample) N = 5). Blood was collected from each rat 1, 2, 4, 8, and 24 hours after administration of the test substance. The collected blood was centrifuged to obtain plasma. Thereafter, oxidation treatment of ubiquinol in plasma and extraction treatment of ubiquinone were performed, and the concentration of ubiquinone was measured using HPLC.
[0058] 以下に、ュビキノールパルク、またはュビキノールとゼラチンを含む組成物(被験物 質)を経口投与した後の血漿中ュビキノン最高血中濃度 (Cmax)と被験物質投与 24 時間後までの血漿中ュビキノン濃度の経時変化曲線下面積 (AUC)値を示す。 [0058] The following is the maximum plasma concentration of ubiquinone (Cmax) after oral administration of ubiquinol parc or a composition containing ubiquinol and gelatin (test substance) and plasma up to 24 hours after administration of the test substance. The area under the time course curve of the concentration of ubiquinone (AUC) is shown.
[0060] ュビキノール結晶と、ゼラチン中にュビキノールが分散した組成物の経口投与後の 血漿中ュビキノン濃度を比較すると、ゼラチン中にュビキノールが分散した組成物の 方が高い血漿中濃度を示し、また、 AUCも高いことが示された。すなわち、ゼラチン 中にュビキノールを共存させると吸収性が向上することが明らかとなった。 [0060] Comparing the plasma ubiquinol concentration after oral administration of ubiquinol crystals and a composition in which ubiquinol was dispersed in gelatin, the composition in which ubiquinol was dispersed in gelatin showed a higher plasma concentration, AUC was also shown to be high. That is, it was revealed that the absorption is improved when ubiquinol is allowed to coexist in gelatin.
[0061] (言周 ゼリー 口口口 [0061] (Kang Zhou Jelly mouth mouth mouth
ゼラチンに加水 ·加熱を行つて溶解させた後、製造例 1で得たュビキノールを加え てホモジナイズし、ュビキノール可溶物(乳化物)を得た。次に、先の乳化物にカゼィ ン及びデキストリンを加えながら加熱し、さらに、果糖ぶどう糖液糖、乳酸 Ca、クェン 酸、香料、クェン酸 Na、ビタミン類を加えて、十分攪拌しながらカップ状容器に充填 することによって、ュビキノールを含有したゼリー状食品を得た。得られたゼリー状食 品の味は良好であった。 After water was heated and dissolved in gelatin, ubiquinol obtained in Production Example 1 was added and homogenized to obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the previous emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, citrate Na, vitamins, and a cup-shaped container with sufficient stirring. The jelly-like food containing ubiquinol was obtained. The taste of the resulting jelly-like food was good.
[0062] (調製例 2)ゼリー状食品 [Preparation Example 2] Jelly-like food
ゼラチンに加水 ·加熱を行つて溶解させた後、製造例 1で得たュビキノールを加え
てホモジナイズし、ュビキノール可溶物(乳化物)を得た。次に、先の乳化物にカゼィ ン及びデキストリンを加えながら加熱し、さらに、果糖ぶどう糖液糖、乳酸 Ca、クェン 酸、香料、クェン酸 Na、ビタミン類を加えて、十分攪拌しながらアルミ複合シートから 形成されたバウチに充填密封することによって、ュビキノールを含有したゼリー状食 品を得た。得られたゼリー状食品の味は良好であった。
Add water and heat to gelatin to dissolve it, then add ubiquinol obtained in Production Example 1. To obtain a ubiquinol-soluble material (emulsion). Next, heat while adding casein and dextrin to the above emulsion, and add fructose-glucose liquid sugar, calcium lactate, citrate, fragrance, sodium citrate, and vitamins, and mix well with stirring. A jelly-like food containing ubiquinol was obtained by filling and sealing the bouch formed from the above. The taste of the obtained jelly-like food was good.
Claims
[1] ュビキノールを含有するゼリー状食品。 [1] A jelly-like food containing ubiquinol.
[2] ゼリー状とするためのゲル化剤を使用することを特徴とする請求項 1記載のゼリー状 ロ P [2] A gelling agent according to claim 1, characterized by using a gelling agent for making a jelly.
[3] ゲル化剤として、寒天、ゼラチン、コンニヤク粉、ぺクチン、片栗でんぷん、葛でんぷ ん、蕨でんぷん(わらびこ)、タピオ力でんぷん及びカラギーナンからなる群より選択さ れる 1種以上のゲル化剤を使用することを特徴とする請求項 1又は 2記載のゼリー状 [3] As a gelling agent, at least one selected from the group consisting of agar, gelatin, konjac flour, pectin, starch starch, katsu starch, bran starch, tapio force starch and carrageenan A gelling agent according to claim 1 or 2, wherein a gelling agent is used.
^ PP o ^ PP o
[4] 粘度が 5.0 X 102 1·0 Χ 105 mPa' s、及び/又は、硬さ力 5 X 104 N/m2以下である 請求項;!〜 3いずれか 1項記載のゼリー状食品。 [4] The jelly according to any one of claims 1 to 3, wherein the viscosity is 5.0 X 10 2 1 · 0 硬 10 5 mPa's and / or the hardness force is 5 X 10 4 N / m 2 or less. Food.
[5] さらに有機酸を含有する請求項;!〜 4いずれか 1項記載のゼリー状食品。 [5] The jelly-like food according to any one of claims 4 to 6, further comprising an organic acid.
[6] さらに抗酸化剤を含有する請求項;!〜 5いずれか 1項記載のゼリー状食品。 [6] The jelly-like food according to any one of claims 5 to 5, further comprising an antioxidant.
[7] さらにビタミン類を含有する請求項 1 6いずれ力、 1項記載のゼリー状食品。 [7] The jelly-like food according to claim 1, further comprising vitamins.
[8] 油脂の含有量が 0. 5重量%未満である請求項;!〜 7いずれか 1項記載のゼリー状 ロ P
[8] The jelly form according to any one of claims 1 to 7, wherein the fat content is less than 0.5% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008535395A JPWO2008035757A1 (en) | 2006-09-22 | 2007-09-21 | Jelly-like food containing ubiquinol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006257240 | 2006-09-22 | ||
JP2006-257240 | 2006-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008035757A1 true WO2008035757A1 (en) | 2008-03-27 |
Family
ID=39200580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/068350 WO2008035757A1 (en) | 2006-09-22 | 2007-09-21 | Jelly-like food containing ubiquinol |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2008035757A1 (en) |
WO (1) | WO2008035757A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009041449A1 (en) * | 2007-09-25 | 2009-04-02 | Kaneka Corporation | Antiobesity agent |
GB2494475A (en) * | 2011-09-12 | 2013-03-13 | Works With Water Nutraceuticals Ltd | A nutraceutical supplement and method of making |
JP2013111064A (en) * | 2011-11-30 | 2013-06-10 | Q P Corp | Bottled liquid seasoning containing grated radish |
WO2014188861A1 (en) * | 2013-05-20 | 2014-11-27 | ユーハ味覚糖株式会社 | Gel-like composition having high ubiquinol content |
JP2014226050A (en) * | 2013-05-20 | 2014-12-08 | ユーハ味覚糖株式会社 | Manufacturing method of reduction type coenzyme q10-containing gummy candy, and gummy candy obtained by the manufacturing method |
JP2015029452A (en) * | 2013-08-01 | 2015-02-16 | 江崎グリコ株式会社 | Frozen jelly |
JP2015105243A (en) * | 2013-11-29 | 2015-06-08 | ユーハ味覚糖株式会社 | Ubiquinol-containing liquid composition |
JP2015104342A (en) * | 2013-11-29 | 2015-06-08 | ユーハ味覚糖株式会社 | Gel composition with high content of ubiquinol |
JPWO2013132670A1 (en) * | 2012-03-05 | 2015-07-30 | テルモ株式会社 | Semi-solidified nutrient |
JP2015209398A (en) * | 2014-04-25 | 2015-11-24 | ユーハ味覚糖株式会社 | High absorption type ubiquinol formulation |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01206960A (en) * | 1988-02-16 | 1989-08-21 | Takenori Kato | Gelatinous substance |
JPH03224452A (en) * | 1990-01-31 | 1991-10-03 | Kyokuto Internatl Corp | Chestnut-like food |
JPH0630714A (en) * | 1992-07-20 | 1994-02-08 | Meiji Seika Kaisha Ltd | Preparation of jelly dough |
JP2002218917A (en) * | 2001-01-23 | 2002-08-06 | Sanei Gen Ffi Inc | Gel composition comprising dispersed insoluble solid material and application thereof |
JP2002255846A (en) * | 2001-02-26 | 2002-09-11 | Sunstar Inc | Oral composition |
JP2003504479A (en) * | 1999-07-12 | 2003-02-04 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | Preparations without crosslinker |
WO2003061395A1 (en) * | 2002-01-18 | 2003-07-31 | Kaneka Corporation | Ubiquinol-enriched fat-containing foods |
JP2004173678A (en) * | 2002-09-30 | 2004-06-24 | Morinaga & Co Ltd | Low water-releasing gel-like composition and method for producing the same |
JP2005143380A (en) * | 2003-11-14 | 2005-06-09 | Domo Corporation:Kk | Nutritional food using snapping turtle egg |
JP2005143365A (en) * | 2003-11-13 | 2005-06-09 | Toshihiro Nomura | Food formulated with fat-soluble effective component |
WO2005097091A1 (en) * | 2004-04-09 | 2005-10-20 | Kaneka Corporation | Composition comprising reduced-form coenzyme q10 and carotenoid compound |
JP2005328803A (en) * | 2004-05-21 | 2005-12-02 | Towa Kagaku Kk | Vitality-promoting and aging-preventing food and method for producing the same |
JP2006022064A (en) * | 2004-07-09 | 2006-01-26 | Asahi Kasei Pharma Kk | Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic |
JP2006070016A (en) * | 2004-08-02 | 2006-03-16 | Kaneka Corp | Whitening composition containing reduced coenzyme q |
-
2007
- 2007-09-21 WO PCT/JP2007/068350 patent/WO2008035757A1/en active Application Filing
- 2007-09-21 JP JP2008535395A patent/JPWO2008035757A1/en active Pending
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01206960A (en) * | 1988-02-16 | 1989-08-21 | Takenori Kato | Gelatinous substance |
JPH03224452A (en) * | 1990-01-31 | 1991-10-03 | Kyokuto Internatl Corp | Chestnut-like food |
JPH0630714A (en) * | 1992-07-20 | 1994-02-08 | Meiji Seika Kaisha Ltd | Preparation of jelly dough |
JP2003504479A (en) * | 1999-07-12 | 2003-02-04 | コグニス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | Preparations without crosslinker |
JP2002218917A (en) * | 2001-01-23 | 2002-08-06 | Sanei Gen Ffi Inc | Gel composition comprising dispersed insoluble solid material and application thereof |
JP2002255846A (en) * | 2001-02-26 | 2002-09-11 | Sunstar Inc | Oral composition |
WO2003061395A1 (en) * | 2002-01-18 | 2003-07-31 | Kaneka Corporation | Ubiquinol-enriched fat-containing foods |
JP2004173678A (en) * | 2002-09-30 | 2004-06-24 | Morinaga & Co Ltd | Low water-releasing gel-like composition and method for producing the same |
JP2005143365A (en) * | 2003-11-13 | 2005-06-09 | Toshihiro Nomura | Food formulated with fat-soluble effective component |
JP2005143380A (en) * | 2003-11-14 | 2005-06-09 | Domo Corporation:Kk | Nutritional food using snapping turtle egg |
WO2005097091A1 (en) * | 2004-04-09 | 2005-10-20 | Kaneka Corporation | Composition comprising reduced-form coenzyme q10 and carotenoid compound |
JP2005328803A (en) * | 2004-05-21 | 2005-12-02 | Towa Kagaku Kk | Vitality-promoting and aging-preventing food and method for producing the same |
JP2006022064A (en) * | 2004-07-09 | 2006-01-26 | Asahi Kasei Pharma Kk | Prophylactic and/or ameliorative agent for arteriosclerosis, functional food, or cosmetic |
JP2006070016A (en) * | 2004-08-02 | 2006-03-16 | Kaneka Corp | Whitening composition containing reduced coenzyme q |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009041449A1 (en) * | 2007-09-25 | 2009-04-02 | Kaneka Corporation | Antiobesity agent |
GB2494475A (en) * | 2011-09-12 | 2013-03-13 | Works With Water Nutraceuticals Ltd | A nutraceutical supplement and method of making |
JP2013111064A (en) * | 2011-11-30 | 2013-06-10 | Q P Corp | Bottled liquid seasoning containing grated radish |
JPWO2013132670A1 (en) * | 2012-03-05 | 2015-07-30 | テルモ株式会社 | Semi-solidified nutrient |
WO2014188861A1 (en) * | 2013-05-20 | 2014-11-27 | ユーハ味覚糖株式会社 | Gel-like composition having high ubiquinol content |
JP2014226050A (en) * | 2013-05-20 | 2014-12-08 | ユーハ味覚糖株式会社 | Manufacturing method of reduction type coenzyme q10-containing gummy candy, and gummy candy obtained by the manufacturing method |
US9757332B2 (en) | 2013-05-20 | 2017-09-12 | Uha Mikakuto Co., Ltd. | Gel-like composition having high ubiquinol content |
JP2015029452A (en) * | 2013-08-01 | 2015-02-16 | 江崎グリコ株式会社 | Frozen jelly |
JP2015105243A (en) * | 2013-11-29 | 2015-06-08 | ユーハ味覚糖株式会社 | Ubiquinol-containing liquid composition |
JP2015104342A (en) * | 2013-11-29 | 2015-06-08 | ユーハ味覚糖株式会社 | Gel composition with high content of ubiquinol |
JP2015209398A (en) * | 2014-04-25 | 2015-11-24 | ユーハ味覚糖株式会社 | High absorption type ubiquinol formulation |
Also Published As
Publication number | Publication date |
---|---|
JPWO2008035757A1 (en) | 2010-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008035757A1 (en) | Jelly-like food containing ubiquinol | |
JP5147239B2 (en) | Coenzyme Q10-containing emulsion composition | |
JP4842824B2 (en) | Coenzyme Q10-containing composition | |
JP6581902B2 (en) | Therapeutic and / or preventive agent or method for promoting energy consumption and / or reducing energy consumption function | |
WO2007037249A1 (en) | Cellooligosaccharide-containing composition | |
EP1755683A2 (en) | Water-soluble coenzyme q10 inclusion complex with beta-cyclodextrin, process of preparing, and use thereof | |
CN105431057A (en) | Methods of maintaining and improving muscle function | |
WO2006112283A1 (en) | Anti-fatigue agent | |
JPWO2003077895A1 (en) | Diabetes composition | |
JP5705898B2 (en) | Liver function improving agent | |
KR20140021988A (en) | Metal ion nanoclusters | |
JPWO2007013556A1 (en) | Cancer prevention composition | |
BR112017005611B1 (en) | ENERGY SUPPLY AGENT, SACARIDIC COMPOSITION, FOOD OR DRINK PRODUCT, AGENT FOR USE IN THE TREATMENT AND PREVENTION OF A DISEASE OR A SYMPTOM, AND USE OF A SACARIDIC COMPOSITION | |
JP2009137916A (en) | Obesity amelioration composition | |
JP5103374B2 (en) | Cardiac dysfunction improving agent or cardiac function maintaining agent | |
JP6456032B2 (en) | Sirt1 activator and use of the Sirt1 activator | |
JP7044306B2 (en) | Leucine blood concentration increase promoter and its uses | |
JPH09309840A (en) | Agent for alopecia | |
JPWO2004080469A1 (en) | Supplements for recovery of hypoglycemia symptoms | |
JP2013192514A (en) | Method for manufacturing oyster extract | |
JP2015003873A (en) | Adiponectin production promoter | |
JP2012206964A (en) | PPAR-α ACTIVITY REGULATING AGENT | |
JP2009051751A (en) | Muscle cell sugar transport promotion action composition | |
JP2004292355A (en) | Anti-stress agent | |
JP4089874B2 (en) | Coenzyme Q10-containing beverage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07807700 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008535395 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07807700 Country of ref document: EP Kind code of ref document: A1 |